Skip to Content
BiomoleculesBiomolecules
  • Review
  • Open Access

17 November 2026

34 Pages

Emerging Therapeutic Strategies Targeting Muscle Wasting in Parkinson’s Disease: From Sarcopenia to Cachexia-like Syndrome

,
,
,
and
1
Victor Babes National Institute of Pathology, 050096 Bucharest, Romania
2
Department of Neurology, Colentina Clinical Hospital, 020125 Bucharest, Romania
3
Department of Cellular and Molecular Biology and Histology, University of Medicine and Pharmacy “Carol Davila”, 011132 Bucharest, Romania
*
Author to whom correspondence should be addressed.

Abstract

Clinically relevant muscle wasting affects a substantial proportion of patients with Parkinson’s disease (PD), although its prevalence varies according to the diagnostic criteria applied. This condition accelerates disease progression, reduces quality of life, and is a poor prognostic indicator associated with increased disability and mortality. Despite its clinical relevance, the molecular mechanisms underlying muscle wasting remain underinvestigated and poorly understood, constituting an unmet clinical need. Currently, there is insufficient evidence to definitively establish PD-associated muscle wasting as true cachexia, a syndrome characterized by systemic inflammation and metabolic dysregulation. Moreover, distinguishing the contribution of age-related sarcopenia from PD-specific pathological mechanisms remains challenging. A deeper understanding of the pathways and molecular signals involved in PD-associated muscle wasting may lead to therapeutic strategies to improve patient outcomes. Given the multifactorial nature of PD muscle wasting—e.g., motor neuron degeneration, aging, oxidative stress, inflammation, protein degradation, mitochondrial dysfunction—our aim is to provide a comprehensive overview of the current data on the cellular, molecular, and systemic mechanisms involved in this process. We also identify emerging therapeutic targets that may help prevent, attenuate, or reverse muscle atrophy in PD. Understanding muscle–brain crosstalk may redefine PD as a systemic rather than neurodegenerative disorder.

1. Introduction

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by intracellular aggregation of α-synuclein and the degeneration of dopaminergic neurons [1], leading to both motor and non-motor symptoms, many of which can be attributed to poor muscle health. There is a robust bidirectional connection between the brain and muscles, spanning from the motor neurons whose axons innervate muscle fibers at the neuromuscular junctions to circulating molecular signals. In PD, degeneration of nigrostriatal dopaminergic neurons disrupts neural impulse transmission to muscles, impairing coordination within the brain–muscle axis. However, some patients exhibit a noticeable reduction in muscle mass, and the underlying causes of this muscle wasting remain elusive [2].
In muscle aging, the sarcopenic decline of muscle fibers and the degeneration of neuromuscular junctions contribute to impaired skeletal muscle performance. In recent years, sarcopenia—a condition marked by aging-associated muscle wasting and weakness—has been recognized as a distinct disease, classified under the International Classification of Diseases (ICD-10-CM, code M62.84) [3]. According to the updated consensus guidelines established by European Working Group on Sarcopenia in Older People (EWGSOP2), the diagnostic focus has shifted toward low muscle strength as the primary indicator of sarcopenia, supported by alterations in muscle mass and physical performance [4].
Notably, muscle wasting appears to be more frequent in PD patients than in age-matched controls [5] with prevalence rates heavily influenced by the specific screening tools applied. While standard diagnostic criteria show that sarcopenia affects 10% to 30% of this population [6,7], including severe cases, these figures often lack precision [2]. Because screening tools vary significantly—some focusing strictly on muscle volume, while others incorporate body weight changes and systemic inflammation—patients with severe PD-associated muscle wasting may be classified as having sarcopenia even when their clinical phenotype extends beyond conventional sarcopenia [2,8]. Consequently, a clear clinical and pathophysiological differentiation between these distinct muscle-wasting phenotypes in PD is urgently needed. This wasting condition accelerates disease progression, severely diminishes quality of life, and serve as a poor prognostic indicator that increases disability and mortality [9]. Despite its clinical relevance, the underlying molecular mechanisms driving this skeletal muscle wasting remain underinvestigated, constituting a critical unmet clinical need [6]. Currently, there is still insufficient evidence to conclusively define PD-associated wasting as a classic cachexia syndrome—which, as defined by the international consensus framework for cancer cachexia, represents a complex metabolic syndrome characterized by a severe loss of muscle mass and systemic inflammation, that cannot be fully reversed by conventional nutritional support alone [10,11]. Distinguishing the precise contribution of age-related sarcopenia from the pathological processes driven by neurodegenerative disease itself remains challenging, complicating efforts to delineate these overlapping muscle-wasting phenotypes.
While clinical and systemic factors such as dysphagia, gastroparesis, depression, and levodopa-induced dyskinesia significantly accelerate weight loss and nutritional deficit in PD patients, the recent literature underscores a broader, bidirectional crosstalk within the muscle–brain axis [12,13].
Over the past few decades, investigations in both humans and animal models have consistently demonstrated that physical exercise exerts robust neuroprotective effects, proving effective in both prevention and management of PD-related symptoms [14,15,16,17]. Skeletal muscle is now recognized as an endocrine organ that secretes myokines, which exert autocrine, paracrine, and endocrine effects [18]. These muscle-derived signals mediate complex regulatory pathways that actively counteract neurodegenerative progression [15,16,19], further supporting the concept that muscle health directly influences central nervous system pathology.
Given the multifactorial nature of muscle degradation in PD, this narrative review aims to provide a comprehensive overview of cellular, molecular and systemic mechanisms driving this process. While prioritizing the intrinsic molecular events that disrupt skeletal muscle homeostasis over purely systemic nutritional deficits, we evaluate potential therapeutic targets capable of preventing, attenuating, or reversing muscle atrophy. Ultimately, understanding these complex muscle–brain interactions may help redefine PD as a systemic, multi-organ disorder rather than a purely isolated neurodegenerative disease. By selectively analyzing contemporary data, this review groups recent findings into distinct thematic categories to deepen the overall understanding of this emerging field.

2. Conceptualizing Muscle Cachexia-like Syndrome in Parkinson’s Disease: Distinctions from Sarcopenia

Because PD predominantly affects older adults, differentiating age-related sarcopenia from PD-specific muscle wasting and from true cachexia remains a clinical and conceptual challenge. While the term “sarcopenia” primarily denotes the age-related, disuse-driven loss of muscle mass and function, “cachexia” refers to a multi-faceted metabolic syndrome characterized by severe muscle wasting and involuntary weight loss driven by an underlying chronic disease [10] (Table 1). Although a subset of PD patients exhibit profound muscle loss indicative for cachexia, this condition is not yet clearly defined or systematically classified within the context of neurodegeneration. Because the current literature does not fully elucidate why only certain patients develop this severe metabolic wasting, the term “cachexia-like syndrome” offers higher clinical and pathophysiological precision. Consequently, this terminology will be used herein to define PD-specific pathological muscle degradation.
Table 1. Cachexia vs. sarcopenia: a comparative overview.
In PD, muscle cachexia-like syndrome is driven by a complex network of interconnected factors, including motor neuron degeneration, accelerated oxidative stress, chronic systemic inflammation, mitochondrial dysfunction, and upregulated protein degradation. This systemic failure impairs physical function and nutritional status, accelerating muscle wasting and ultimately exacerbating PD severity through a pathogenic feedback loop. Crucially, muscle loss in PD not only diminishes the patient’s quality of life but may also compromise treatment efficacy, mirroring observations in other wasting diseases such cancer.
To guide clinical and theoretical distinctions, the key differences between classic sarcopenia and PD-associated cachexia-like syndrome are summarized below.
Determining the relative contributions of age-related sarcopenia versus the neurodegenerative processes of PD remains difficult for clinicians. Recently, Murphy and Lynch highlighted several specific factors that uniquely impair skeletal muscle health in patients with Parkinsonian syndromes [9]. For instance, camptocormia occurs in approximately 7% of PD patients, specifically affecting paravertebral muscles and causing an abnormal flexion of the thoracolumbar spine when standing or walking. Histologically, this is accompanied by loss of myofibrillar integrity, decreased oxidative enzyme activity, and connective tissue infiltration. Furthermore, over 50% of patients experience reduced efficiency of the masseter and temporal muscles leading to severe eating difficulties, while pharyngeal and cardiac muscles are similarly vulnerable to damage [9]. In skeletal muscles, calcium homeostasis is also disrupted; an in vivo study on mice with MPTP-induced PD demonstrated a significantly reduced expression of Ca2+ regulatory proteins, including ryanodine receptors, calsequestrin 1 and triadin [20]. This downregulation impairs sarcoplasmic reticulum Ca2+ release, ultimately compromising muscle contraction, independent of standard aging.
Broadly, skeletal muscle loss in PD is driven by an array of direct and indirect pathological conditions. Key contributors include malnutrition, reduced physical activity, sleep disturbances, accumulation of α-synuclein in skeletal muscle, motor neuron loss and neuromuscular junction (NMJ) dysfunction, hormonal imbalances, and intestinal microbiota dysbiosis.
At the molecular scale, these catabolic conditions trigger muscle atrophy through the depletion of proteins, cellular organelles, and cytoplasm, which reduces both muscle fiber size and number. This destructive process is primarily mediated by the ubiquitin–proteasome system (UPS) and autophagy–lysosome system [21]. Beyond these metabolic shifts, genetic factors also drive generalized muscle atrophy through the involvement of a specific set of genes regulated at the mRNA level, known as atrogenes (atrophy-related genes). These atrogenes serve as the primary master regulators of muscle wasting, controlling the upregulation of the cellular degradation pathways, responsible for breaking down contractile proteins, and executing organelle degradation [21,22].
While this review prioritizes the underlying molecular mechanisms and potential pharmacological targets of PD-associated muscle wasting, clinical awareness remains the critical first step. Effective translation of these molecular strategies into practice will ultimately require their systematic integration with routine clinical assessments, including targeted sarcopenia screening, body composition analysis (such as DXA or BIA), and comprehensive nutritional risk evaluations.

3. Methods

Given the evolving terminology surrounding muscle degradation in Parkinson’s disease, we employed a narrative, iterative search strategy rather than rigid screening protocols using a “snowballing” approach, moving from foundational papers to recent studies; electronic databases, including Web of Science, PubMed and Google Scholar, were searched using broad terms such as: Parkinson’s disease muscle atrophy, PD sarcopenia, PD muscle cachexia, PD muscle wasting, and muscle atrophy signaling pathways, all combined with “therapy” or “treatment”. Articles were selectively included based on their relevance to systemic wasting and structural muscle loss in PD.
A major challenge identified during the literature selection was terminological inconsistency; similar clinical presentations of muscle loss in PD were interchangeably labeled as sarcopenia, muscle cachexia, muscle atrophy, or muscle wasting, depending on the study.
Conceptual framework and definitions
To ensure conceptual clarity and address these inconsistencies, we establish the following operational definitions for this review:
Sarcopenia: A distinct clinical syndrome characterized by the progressive, generalized loss of skeletal muscle mass and strength, primarily associated with aging (primary sarcopenia) or physical inactivity, poor nutrition, and chronic disease (secondary sarcopenia). In this review, it strictly refers to cases matching established diagnostic criteria (e.g., EWGSOP2 guidelines), focusing on muscle quality and physical performance. It is crucial to note that the reported prevalence of sarcopenia in PD fluctuates significantly between 10% and 30%. This wide variation is largely driven by heterogeneity in diagnostic criteria and screening methods across clinical trials. For instance, diagnostic frameworks established by the European Working Group on Sarcopenia in Older People (EWGSOP1 vs. EWGSOP2), the Asian Working Group for Sarcopenia (AWGS), and the Foundation for the National Institutes of Health (FNIH) utilize distinct cutoff thresholds for muscle mass and functional impairment. While updated guidelines like EWGSOP2 emphasize low muscle strength as the primary indicator, applying quick screening tools like the SARC-F questionnaire often overestimates or underestimates the actual prevalence due to a confounding overlap with intrinsic PD motor symptoms (e.g., bradykinesia and rigidity). Consequently, these disparate operational definitions directly shift diagnostic boundaries and alter epidemiological cross-comparisons.
Muscle wasting: An umbrella term used in this paper to describe any involuntary, objective loss of skeletal muscle mass, regardless of the underlying etiology. It serves as a descriptive term when the precise metabolic or diagnostic criteria for sarcopenia or cachexia are not fully specified.
Cachexia: A complex metabolic syndrome associated with an underlying chronic disease, characterized by severe loss of muscle mass with or without loss of fat mass. Its key diagnostic hallmarks include systemic inflammation, anorexia, tissue wasting, and elevated energy expenditure that cannot be fully reversed by conventional nutritional support alone.
PD-associated cachexia-like syndrome: A term we propose exclusively for the subset of PD patients presenting with profound, involuntary muscle wasting accompanied by metabolic dysregulation or systemic inflammation, mimicking classic cachexia features. This terminology avoids implying that PD-related muscle loss fully fulfills established diagnostic criteria for clinical cachexia, while acknowledging the severe metabolic complications that extend beyond age-related sarcopenia.
To preserve bibliographic accuracy, this review retains the original nomenclature used by the authors of the cited primary studies, even where historical definitions overlap or conflict. However, when synthesizing these findings and discussing clinical implications, we strictly adhere to the operational definitions established above.

4. Mechanistic Drivers of Muscle Cachexia-like Syndrome as Potential Therapeutic Targets in Parkinson’s Disease

The mechanistic drivers of muscle cachexia-like syndrome in PD involve a pathological cascade of protein imbalance, systemic inflammation, and metabolic and energetic dysfunctions. In a subset of patients, the loss of muscle mass is not merely a consequence of reduced mobility, but is actively driven by several distinct molecular and systemic factors, which represent promising therapeutic targets.

4.1. PD-Associated Proteins and Proteostatic Imbalance

Proteins implicated in PD pathogenesis may contribute to muscle dysfunction, ranging from α-synuclein and mitochondrial regulators to inflammatory mediators and muscle atrophy markers. These proteins drive NMJ degradation, mitochondrial dysfunction, and oxidative stress, while concurrently impairing muscle regeneration. The potential therapeutic targets, categorized according to the context of the supporting evidence, are summarized in Table 2.

4.1.1. Alpha-Synuclein

Pathological α-synuclein accumulates not only in the brain under pathological conditions, but also in peripheral organs, such as the gut [23], kidneys [24], skeletal muscle [25]. Under physiological conditions, α-synuclein is expressed in skeletal muscle, localizing postsynaptically at the NMJ [25], where it regulates the exocytosis and endocytosis of synaptic vesicles [26] by interacting with the SNARE (Soluble NSF Attachment Protein Receptor) complex, endophilin A and Rab GTP-ases. Under pathological conditions, a high density of aggregated α-synuclein within intramuscular motor neurons and NMJs correlates with clinical symptoms like dysphagia [27]. Experimental findings suggest that α-synuclein may translocate from neuromuscular structures into myofibers and interact with mitochondria, potentially disrupting mitochondrial homeostasis. However, the occurrence and pathological significance of this mechanism in human PD skeletal muscle remain to be established. Transgenic mThy-hSNCA mice overexpressing α-synuclein exhibit intramuscular mitochondrial oxidative stress, altered muscle satellite cell metabolism, impaired myoblast differentiation, and delayed muscle regeneration [28].
Abnormal α-synuclein aggregation in skeletal muscle is also observed in non-PD pathologies, such as inclusion body myositis (IBM), amyotrophic lateral sclerosis (ALS), and ankylosing muscular dystrophy [25], where it is associated with reduced fiber size, decreased muscle mass, and a fiber-type shift from fast-twitch to slow-twitch. A similar phenotype occurs in transgenic mice overexpressing human α-synuclein. Despite these findings, the precise role of α-synuclein in skeletal muscle physiology remains underinvestigated. Additionally, α-synuclein interacts with metabolic pathways; it modulates insulin secretion and glucose uptake, and acute intravenous administration in mice stimulates muscle glucose uptake [29,30].
Peripheral expression of α-synuclein is modulated by upstream muscle kinases. In a MPTP-induced model of PD, decreased muscle expression of serum/glucocorticoid-regulated kinase 1 (SGK1)—a key inhibitor of proteolysis and autophagy—correlates with elevated muscle α-synuclein levels [31]. Similarly, MPTP intoxication downregulates serine/arginine-rich protein-specific kinase 3 (Srpk3) in skeletal muscle, a kinase controlled by the muscle-specific enhancer Mef2, leading to increased α-synuclein expression [32]. While these animal and in vitro models provide valuable mechanistic insights, it has been proposed, but not yet definitively demonstrated in human PD muscle, that muscle-derived α-synuclein can enter systemic circulation via exocytosis [33] or within erythrocyte-derived extracellular vesicles, theoretically contributing to central pathology via blood–brain barrier crossing [34,35]. Extravasation of red blood cells has been detected in the striatum of PD patients [36,37], but a definitive causal link to peripheral muscular propagation remains speculative.
Taken together, while these data suggest that skeletal muscle represents a critical peripheral site involved in α-synuclein-driven pathogenesis, the precise clinical relevance of this cross-tissue bidirectional propagation in human patients remains a working hypothesis rather than an established physiological fact.
Therapeutic targets
(i) Targeting intramuscular α-synuclein accumulation using mitochondria-targeted antioxidants, such as Mito-TEMPO, has shown preclinical efficacy in mitigating localized oxidative stress [28]. Although other studies have described pharmacological interventions targeting mitochondrial α-synuclein aggregation in PD independently of muscle tissue, these findings could establish a foundation for developing novel treatments specifically for PD-related muscle cachexia-like syndrome.
(ii) Insulin resistance (IR) and its bidirectional relationship with α-synuclein represent another viable therapeutic avenue, potentially utilizing repositioned anti-diabetic drugs. Given that serum α-synuclein levels inversely correlate with IR indicators in PD patients and SNCA-deficient models, repositioning anti-diabetic drugs represents a viable strategy to restore muscle glucose homeostasis. However, the exact molecular mechanisms by which α-synuclein modulates insulin signaling remain to be fully elucidated [30].
(iii) SGK1 and Srpk3 signaling pharmacological strategies aimed at maintaining physiological SGK1 and Srpk3 expression offer an experimental avenue to suppress muscle proteolysis and systemic protein propagation [30,31].
(iv) Extracellular α-synuclein immunotherapy. Monoclonal antibodies (e.g., prasinezumab) have been investigated as potential disease-modifying strategies in PD. However, their ability to prevent α-synuclein uptake by skeletal myofibers, limit peripheral propagation, or attenuate PD-associated muscle wasting remains hypothetical and has not been directly demonstrated [38].

4.1.2. Parkin

Parkin, an E3 ubiquitin-ligase [39], is another key protein involved in the pathophysiology of PD. Mutations in its gene, PARK2, are responsible for most cases of the autosomal recessive form of early-onset PD [40]. While these mutations primarily drive central neurodegeneration, accumulating evidence emphasizes that PD-related muscle wasting is also governed by distinct, muscle-autonomous effects. It has been shown that Parkin is expressed not only in the brain, but also in skeletal [41] and cardiac muscle [40,42,43], where it plays an important role in regulating mitochondrial function. Notably, a subset of PD patients develop distinct myopathies [44,45], directly linked to Parkin dysfunction, highlighting its relevance in maintaining skeletal muscle homeostasis.
In skeletal muscle, Parkin is expressed in muscle fibers, myoblasts, myotubes and satellite cells. Its genetic deletion in satellite cells severely impairs their differentiation capacity by disrupting the core myogenic program, compromising mitophagy and altering mitochondrial protein expression [46]. Thus, Parkin acts as a key modulator of myogenic factors involved in myofiber maturation. Mechanistically, Parkin coordinates a muscle-autonomous quality control system independent of central nervous system pathology via the canonical PINK1/Parkin pathway [47]. Under conditions of mitochondrial stress [39,48], PTEN-induced putative kinase 1 (PINK1) accumulates on the outer mitochondrial membrane and phosphorylates ubiquitin, recruiting cytosolic Parkin [49]. Once hyperactivated, Parkin drives the ubiquitin-mediated degradation of the mitochondrial fusion proteins, mitofusin-1 and mitofusin-2 [39]. This targeted degradation prevents damaged mitochondria from fusing with the healthy mitochondrial network, isolating them for selective removal via autophagy–lysosome pathways (mitophagy) [39].
Beyond mitochondrial clearance, this muscle-autonomous mechanism supports cellular proteostasis by facilitating the degradation of misfolded and aggregated proteins through the ubiquitin–proteasome system [50]. Parkin also autonomously regulates mitochondrial biogenesis via the Parkin-PARIS (Parkin Interacting Substrate)–PGC-1α (Peroxisome proliferator-activated receptor gamma coactivator 1-alpha) axis. Under physiological conditions, Parkin binds to and targets the transcriptional repressor PARIS for proteasomal degradation [51]. Parkin deficiency leads to pathological PARIS accumulation, which transcriptionally represses PGC-1α—the master regulator of mitochondrial biogenesis—thereby halting the synthesis of new mitochondria [44,49]. Consequently, Parkin loss drives elevated reactive oxygen species (ROS) emissions, energy depletion, and progressive muscle degeneration. While these pathways are highly compelling, it is very important to note that evidence linking Parkin disruption directly to severe muscle cachexia-like phenotypes is currently derived from experimental models rather than confirmed human PD muscle biopsies. In vitro knockdown of Parkin in C2C12 myotubes accelerates baseline proteasomal activity, while Parkin knockout mice subjected to fasting display an exacerbated muscle atrophy phenotype accompanied by hyperactivated autophagy flux [52]. Similarly, antisense inhibition or mutations of PINK1/Parkin in Drosophila models lead to degeneration of flight muscles, mitochondrial enlargement, energy depletion, loss of dopaminergic neurons, structural abnormalities, and a shortened life span [53]. The functional consequences of Parkin disruption include impaired mitochondrial activity, increased mitochondrial fragmentation, and defective muscle contractility. These alterations contribute to muscle atrophy and weakness, as well as impaired regenerative capacity. Conversely, Parkin overexpression in vivo (PARK2 knockout mice) restores mitochondrial bioenergetics in skeletal muscle maintaining the contractile function [43], improves mitochondrial function, and protects myofibers against proteotoxic stress enhancing the clearance of damaged mitochondria and maintaining cellular homeostasis [54].
Therapeutic targets
(i) Increase in Parkin expression. The overexpression of Parkin has shown the potential to counteract skeletal muscle atrophy by increasing the mitochondrial mass [55] in a sepsis mouse model. Similar studies, conducted on middle-aged mice indicated that after four months of Parkin overexpression, there was an increase in both muscle mass and strength [56]. Because Parkin facilitates mitophagy, increasing its expression enhances mitochondrial quality, prevents the accumulation of dysfunctional mitochondria, and improves overall muscle function. Similar findings were observed in a mouse model of Duchenne muscular dystrophy (DMD). Parkin was overexpressed by muscular injections of adeno-associated viruses, resulting in muscle hypertrophy, an increase in muscle mass, and an increase in fiber cross-sectional area. Furthermore, Parkin overexpression enhanced the Acceptor Control Ratio, an index of mitochondrial bioenergetic efficiency, and attenuated mitochondrial H2O2 emission (a surrogate for mitochondrial ROS production).
(ii) Resistance and aerobic exercise interventions. Regarding the non-pharmacological strategies that stimulate natural cellular mechanisms, including Parkin pathways, resistance training is the most effective intervention for enhancing muscle protein synthesis and counteracting muscle atrophy in PD [9]. Aerobic exercise stimulates mitochondrial biogenesis [57].

4.2. Imbalanced Proteostasis Pathways in Skeletal Muscle: Ubiquitin–Proteasome System and Autophagy–Lysosome System

Imbalanced proteostasis—the disruption of the dynamic equilibrium among protein synthesis, folding, trafficking, and degradation—is a primary driver of neurodegenerative pathologies. Although Parkinson’s disease is traditionally classified as a central nervous system disorder, identical proteostatic disruptions occur autonomously within the peripheral skeletal muscle. Structural and functional muscle integrity is governed by three interconnected pathways: the ubiquitin–proteasome system, the autophagy–lysosome system and mitochondrial quality control. Pathological disruption of any single pathway triggers a deleterious cascade that destabilizes the others, acceleration progressive muscle degradation.

4.2.1. Ubiquitin–Proteasome System

The ubiquitin–proteasome system (UPS) is the primary pathway for clearing misfolded or defective proteins. In PD-associated muscle wasting, localized mitochondrial dysfunction impairs ATP production, directly compromising energy-dependent protein ubiquitination and accelerating protein aggregation. This accumulation of damaged proteins, contributes to mitochondrial dysfunction and muscle mass loss [58].
Proteolysis in striated muscle is regulated by specific E3 ubiquitin ligases that target substrates for proteasomal degradation through polyubiquitination. Muscle RING finger 1 (MuRF1/TRIM63) and muscle atrophy F-Box (Atrogin-1/MAFbx) represent the principal atrogenes driving muscle atrophy [59]. Additional atrophy-related E3 ligases, particularly those upregulated during neurogenic denervation include: Muscle Ubiquitin Ligase of SCF complex in Atrophy-1 (MUSA1), Specific of Muscle Atrophy and Regulated by Transcription (SMART), and F-box and leucine-rich protein 22 (Fbxl22) [59]. Transcriptional control of these atrogenes is primarily mediated by forkhead box O (FoxO) transcription factors and myogenin. Elevated levels of Atrogin-1 and MuRF1 serve as established biomarkers of active muscle wasting [60].
Mechanistically, Atrogin-1 targets the eukaryotic translation initiation factor 3 subunit F (eIF3-F), myoblast determination protein 1 (MyoD), calcineurin A, and Insulin Receptor Substrate 1 (IRS-1) for degradation, while MuRF1 selectively dismantles structural components, including myosin heavy chain, myosin-binding protein C, troponin I and T, and titin [61]. Notably, genetic deletion of Atrogin-1 or MuRF1 confers resistance to denervation-induced muscle atrophy in vivo [60]. Reflecting its relevance to PD pathology, MuRF1 expression is significantly elevated in the soleus muscle of middle-aged Parkin-deficient mice (Parkin-/-), confirming its role as a key downstream mediator of PD-associated cachexia-like syndrome [62].
Therapeutic targets
Inhibiting E3 ligases remains a complex therapeutic challenge due to incomplete structural insights into substrate recognition and proteasomal delivery. However, small-molecule inhibitors designed to disrupt MuRF1 activity and its specific interaction with titin have shown preclinical promise. A preclinical study using C2C12 cells and mice with induced cardiac cachexia demonstrated that small-molecule inhibition attenuated muscle wasting and cardiac contractile dysfunction by downregulating apoptosis and ubiquitin–proteasome-dependent proteolysis [63]. Furthermore, while in vivo overexpression of the denervation-responsive ligase Fbxl22 induces severe myopathy, its targeted RNAi knockdown in a MuRF1-knockout background exerts a robust, additive muscle-sparing effect post-denervation [64]. These findings suggest that simultaneously targeting multiple E3 ubiquitin ligases represents a viable synergistic approach to counteract neurogenic muscle loss.

4.2.2. Autophagy–Lysosome System

The autophagy–lysosome system serves as a second major intracellular degradation pathway; however, its chronic overactivation or impairment contributes heavily to muscle fiber atrophy. A strict compensatory relationship exists between the UPS and autophagy; for example, genetic disruption of the proteasome (via muscle-specific Rpt3 knockout) triggers a compensatory upregulation of the autophagic flux to mitigate proteotoxicity [59]. Macroautophagy is the predominant autophagic mechanism in skeletal muscle, utilizing abundant lysosomal proteases known as cathepsins. Under prolonged catabolic or septic stress, cathepsin L is highly upregulated, correlated directly with accelerated muscle mass loss [65].
In PD the autophagy–lysosome system is intrinsically impaired [66], triggering muscle atrophy through the accumulation of defective organelles and protein aggregation that ultimately induce myofiber apoptosis. The transcription factor FoxO3 acts as a principal upstream regulator of this system, concurrently driving the transcript of core atrogenes and mitophagy-related genes. Similarly, transcription factor EB (TFEB) and transcription factor E3 (TFE3)—members of the MiT/TFE family—regulate the expression of the coordinated lysosomal expression and regulation (CLEAR) network. Crucially, downstream events such as prolonged reactive oxygen species (ROS) accumulation and disrupted intracellular Ca2+ dynamics further accelerate this autophagic dysregulation [67].
The intersection of autophagic failure and mitochondrial decline is prominently illustrated by Parkin deficiency. In Parkin KO mice subjected to starvation, the profound reduction in muscle mass is directly driven by the pathological overactivation of autophagy-related genes [52]. Additionally, genetic screens in Drosophila have identified Gyf/CG11148 (the human ortholog of which is mutated in a type of familial PD), as a critical regulator of muscle autophagic homeostasis [68]. Null mutants for this gene exhibit a reduced life span and early impairment of mobility, associated with neurodegeneration, severe muscle wasting, accumulation of ubiquitinated proteins, and dysfunctional mitochondria.
Therapeutic targets
Modulating specific stages of the autophagy–lysosome pathway is a promising strategy to restore skeletal muscle proteostasis. Within this framework, the transcriptional factor TFEB serves as a prime therapeutic target. Pharmacological enhancement of TFEB activity upregulates lysosomal biogenesis, which accelerates the clearance of proteotoxic aggregates and maintains organelles homeostasis [69]. Similarly, rescuing or preserving PINK1/Parkin-mediated mitophagy pathway protects against fasting-induced muscle fiber atrophy and stabilizes myofibrillar architecture [52].
While targeted modulation of FoxO family members remains an exploratory avenue to halt atrogene induction and muscle-related neurodegeneration [70], resistance and aerobic physical training represent validated, non-pharmacological clinical interventions [71]. Exercise effectively stimulates physiological autophagy–lysosomal flux, clearing damaged structures without inducing catabolic muscle wasting.
Table 2. PD-associated proteins and proteostatic pathways as potential therapeutic targets.

4.3. Mitochondrial Dysfunction

Skeletal muscle architecture relies fundamentally on mitochondrial networks to meet its high energetic demands. Disruptions in organelle dynamics—characterized by fusion and fission imbalances or defective mitophagy—underlie progressive muscle wasting across various pathological states, including disuse atrophy and secondary sarcopenia [72,73,74,75,76,77,78].
In PD, skeletal muscle mitochondrial dysfunction frequently precedes the onset of classic motor symptoms. Histopathological analyses of muscle biopsies from PD patients reveal a prominent reduction in mitochondrial mass and severe deficiencies in the mitochondrial respiratory chain [79]. Specifically, patient-derived muscle tissue demonstrates a marked loss of mitochondrial complex I activity that occurs independently of mitochondrial DNA (mtDNA) abnormalities, suggesting a distinct PD patient subpopulation characterized by muscle-specific complex I restriction [80]. Similarly, in rotenone-induced murine models of PD, progressive motor impairment correlates with a substantial reduction in complex I and II activities, accompanied by distinct remodeling of the skeletal muscle lipidome [81].
At the signaling level, these mitochondrial network alterations induce an energy imbalance that activate the catabolic muscle program. This bioenergetics deficit triggers AMP-activated protein kinase (AMPK) signaling, which subsequently drives FoxO3-dependent atrogene transcription [82]. Chronic mitochondrial disruption further elevates reactive oxygen species (ROS) emissions, escalating localized oxidative stress and ultimately inducing myofiber apoptosis or necrosis [82,83,84].
While physical mitochondrial fission naturally facilitates the isolation of damaged components, its chronic overactivation in the absence of functional quality control machinery—such as the PINK1/Parkin mitophagy axis discussed in Section 4.1.2—accelerates structural muscle degradation and biomarker upregulation (e.g., MuRF1) [61]. Consequently, preserving mitochondrial bioenergetics and network homeostatic balance is vital to halt PD-associated cachexia-like syndrome.
Therapeutic targets
Therapeutic interventions (Table 3) could target the restoration of energy balance and the reduction in oxidative stress by pharmacological interventions.
Table 3. Mitochondrial quality control and bioenergetic targets in PD muscle wasting.
A critical approach involves the modulation of quality control mechanisms, enhancing mitophagy by targeting the PINK1/Parkin axis to ensure the efficient removal of damaged organelles before they trigger apoptosis [85].
A non-pharmacologic strategy remains the resistance and aerobic exercise to stimulate mitochondrial remodeling. Exercise not only enhances respiratory chain efficiency but also counteracts the FoxO3-mediated proteolytic program [81].

4.4. Neuromuscular Junction Degeneration

Motor symptoms and peripheral muscle weakness in PD are heavily driven by the progressive dysfunction of the neuromuscular junctions (NMJs). This disruption of the physical and signaling connection between peripheral motor axons and skeletal muscle fibers represents a core driver of PD-associated cachexia-like syndrome. Pathological accumulation of α-synuclein aggregates within motoneuron axons and presynaptic terminals directly inhibits acetylcholine release, triggering localized mitochondrial oxidative stress and accelerating sarcomeric degradation, as detailed in Section 4.1.1.
Yang and colleagues demonstrated in an animal model that the aggregation of α-synuclein destabilizes the acetylcholine release at the level of the NMJ inducing intramuscular mitochondrial oxidative stress [28]. They also observed the degeneration of NMJs due to the disruption of mitochondrial cristae. This fact can be one of the explanations for the appearance of muscle atrophy in patients with PD.
The structural organization and phenotypic distribution of skeletal muscle fibers are fundamentally dictated by their innervation status and NMJ stability. Clinical evaluation of PD patients demonstrates that chronic denervation accelerates motor unit remodeling and induces pathological myofiber type grouping [86]. While age-related motor unit remodeling naturally reduces the efficiency of muscle activation, the underlying PD pathology severely aggravates these processes, leading to the destabilization of the postsynaptic membrane, type I myofiber grouping, and a selective, profound loss of fast-twitch type II motor units [87]. As an established clinical standard, resistance exercise training serves as an intervention to potentially mitigate these structural manifestations [86].
To trace these degenerative shifts, recent clinical studies in patients with PD exhibiting advanced age-related muscle loss have evaluated specific circulating biomarkers of NMJ stability, including C-terminal agrin fragment-22 (CAF22), brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF). These circulating factors demonstrate a robust, dynamic correlation with clinical metrics like handgrip strength, confirming their utility as sensitive biomarkers for the early detection and longitudinal monitoring of peripheral wasting [88].
Beyond human cohorts, genetic screening in Drosophila models of PD has uncovered critical synaptic trafficking mechanisms governing NJM integrity [89]. For instance, heterozygous park13 (park13/+) mutants exhibit a severe downregulation of the Rab11 trafficking protein—a small Ras GTPase required for adult muscle development and synaptic organization. This deficit results in profound muscle degeneration, impaired cytoskeletal assembly, and structural abnormalities at the larval NMJ, characterized by abnormal expansion of bouton number and restricted bouton size [89]. Mechanistically, Rab11 interacts directly with Bruchpilot (Brp), a presynaptic scaffolding protein required for synaptic neurotransmission. Consequently, impaired Brp-mediated transmission underpins the structural defects and muscle vulnerability observed in these models.
Therapeutic targets
The potential therapeutic targets are categorized according to the biological and clinical context of the supporting evidence in Table 4.
Table 4. Potential therapeutic targets and biomarkers in NMJ degeneration.
Recent studies suggest several targets: NMJ components (e.g., agrin, MuSK—muscle-specific kinase, LRP4—low-density lipoprotein receptor-related protein 4, and rapsyn); the delivery of neurotrophic and growth factors to stimulate axonal sprouting and reinnervation; high-intensity resistance training to improve motor unit remodeling and NMJ stability; calcium channel modulation to reduce mitochondrial stress and cellular Ca2+ overload; and the use of anti-inflammatory and antioxidant agents to target NMJ neuroinflammation (via JAK inhibitors or TNF-α blockers) and mitochondrial α-synuclein [9,,90,91,92].

4.5. Inflammation and Oxidative Stress

Chronic, low-grade systemic inflammation is a common feature of PD that directly drives peripheral muscle proteolysis. Pro-inflammatory cytokines promote a catabolic muscle state while simultaneously inhibiting protein synthesis pathways [9]. Elevated circulating levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and specific inflammasome components characterize both earl-stage PD and classic muscle cachexia [2]. IL-6 promotes inflammatory cell infiltration into myofibers via the nuclear factor kappa B (NF-kB) pathway, disrupts mitochondrial energy homeostasis, and affects muscle protein synthesis. Mechanistically, recent evidence from other systemic wasting syndromes indicates that this IL-6/NF-κB axis requires the recruitment of epigenetic cofactors, such as Bromodomain Containing 4 (BRD4), to directly activate the muscle-wasting gene transcription program [93]. Similarly, TNF-α activates NF-kB signaling through tumor necrosis factor receptor-associated factor 6 (TRAF6) induction, directly upregulating core atrogenes (e.g., MuRF-1, MAFbx) via the UPS. Concurrently, NF-κB activation and CRP-mediated mitogen-activated kinase (MAPK) signaling promote muscle catabolism by reducing the phosphorylation of protein kinase B (AKT) and ribosomal protein kinase beta-1 (S6K1), ultimately driving a profound reduction in skeletal muscle mass [2].
The neuroinflammatory environment is inextricably linked to mitochondrial oxidative stress within PD skeletal muscle. The skeletal muscles of patients with Parkinson’s disease exhibit altered morphology and a decreased capacity for oxidative phosphorylation, alongside increased production of peroxides. This situation leads to heightened oxidative stress [94]. This hyperproduction of reactive oxygen species (ROS) drives myofiber apoptosis, induces focal necrosis, and severely disrupts the homeostatic microenvironment between motor neurons and muscle satellite cells, adversely impacting the muscle regeneration process [95].
Therapeutic targets
To halt this peripheral muscle breakdown, clinical and experimental strategies target the neutralization of pro-inflammatory cascades, the scavenging of mitochondrial ROS, and the preservation of redox balance. Recent evidence indicates that chronic, low-grade systemic inflammation and excessive ROS significantly impact peripheral muscle tissue, leading to atrophy, stiffness, and weakness.
The neuroprotective effects of exercise in PD are well-known, attributed to crosstalk along the brain–muscle axis [9]. Regular aerobic activity (e.g., walking, cycling, dancing) increases the activity of non-enzymatic and enzymatic antioxidants, reducing oxidative stress and improving mitochondrial quality. Resistance training is crucial for reversing muscle atrophy and improving muscle strength in PD patients.
Pharmacological and molecular approaches focus on scavenging ROS, protecting mitochondria, and modulating the immune system to stop peripheral muscle breakdown. Most studies in this regard have been done on the brain, but their findings can also be extrapolated to muscle tissue, which is similarly affected in many PD patients. Agents such as MitoQ (mitoquinone mesylate) are designed to target mitochondria specifically, reducing the ROS generated by dysfunction within the muscle cells [96]. Nuclear factor erythroid 2-related factor 2 (Nrf2) pathway activators can boost endogenous antioxidant defenses (e.g., glutathione synthesis) to improve redox balance and maintain NMJ integrity [97]. By binding excess iron (which accumulates in PD and triggers ROS production via the Fenton reaction), compounds like deferoxamine (DFO) can reduce oxidative stress in dopaminergic neurons [98], an aspect that could be considered for muscle tissue as well. Strategies that inhibit inflammatory mediators—such as the NLRP3 inflammasome or NF-κB pathway—show promise in reducing IL-6 and TNF-α-driven muscle loss [99].
An emerging molecular target linking these neuroinflammatory cascades with peripheral muscle catabolism is Bromodomain Containing 4 (BRD4), a member of the bromodomain and extraterminal (BET) protein family. Rather than acting as isolated tissue-specific factors, BET proteins function as epigenetic cofactors that orchestrate cellular responses to chronic inflammation and impaired proteostasis. In neurotoxic models of PD, pharmacological targeting of BET proteins has demonstrated significant neuroprotective properties by suppressing microglial activation and curtailing pro-inflammatory cytokine transcription. However, it is critical to emphasize that all current evidence establishing BRD4 as a direct epigenetic driver of muscle atrophy program—where it coordinates a pathological IL-6-dependent AMPK nuclear signaling pathway converging on the FoxO3 transcription factor—derives exclusively from oncology and tumor cachexia models. Currently, direct experimental or clinical evidence linking BET proteins specifically to human or animal PD skeletal muscle is entirely lacking, meaning BRD4 must be classified strictly as an unproven, early-stage translational hypothesis. Consequently, if BET inhibitors (e.g., apabetalone) progress into clinical trials for PD, clinical trial designs must incorporate precise secondary outcome indicators to robustly evaluate whether peripheral skeletal muscle experiences any therapeutic benefit. Future research should utilize a multimodal battery of observable indicators. Structural muscle preservation should be monitored using dual-energy X-ray absorptiometry (DXA) or bioelectrical impedance analysis (BIA) to track appendicular lean mass, alongside magnetic resonance imaging (MRI) to quantify cross-sectional muscle volume and muscle fat fraction (myosteatosis). Functional skeletal muscle benefits must be objectively evaluated using standardized clinical endpoints, including handgrip strength, gait speed, the 6-min walk test (6MWT), and patient-reported outcomes to capture disease-specific fatigue. Finally, these structural and functional readouts should be correlated with circulating biomarkers, specifically longitudinal tracking of systemic inflammatory mediators such as high-sensitivity C-reactive protein (hs-CRP) and circulating interleukin-6 (IL-6), to explore whether BET inhibition is associated with improvements in skeletal muscle outcomes and changes in systemic inflammation [100].
Nutritional therapies, including antioxidant-rich diets and supplements (e.g., Coenzyme Q10, Vitamin E, Vitamin D, Omega-3 fatty acids, and polyphenols) have been investigated in PD for their potential effects on oxidative stress, inflammation, and clinical symptoms; however, their effects on PD-associated muscle wasting remain unclear [101].
A therapeutic target to consider is the modulation of the gut microbiome. Gut dysbiosis has been associated with systemic inflammation in PD, providing a rationale for therapeutic modulation of the gut–muscle axis; however, whether microbiome-targeted interventions can prevent or attenuate PD-associated muscle wasting remains unknown.
These multimodal interventions are categorized according to the biological and clinical context of the supporting evidence in Table 5.
Table 5. Potential therapeutic targets in muscle inflammation and oxidative stress.

4.6. Endocrine Signaling and Trophic Factors as Therapeutic Strategies

Myokines are cytokines, peptides or proteoglycans produced in skeletal muscle in response to muscle contraction acting through autocrine, paracrine, and endocrine mechanisms. They exert systemic effects across various organs through diverse pathways [18]. In the context of PD, where reduced physical activity and muscle dysfunction are prominent, alterations in myokine signaling may contribute to the development and progression of muscle cachexia. Few myokines were systematically investigated for their potential involvement in muscle atrophy in neurodegenerative diseases, such as myostatin, irisin, follistatin, brain-derived neurotrophic factor (BDNF), decorin, and interleukin-6 (IL-6). Many of them have an influence in reducing oxidative stress and inflammation and enhancing mitochondrial biogenesis. They are modulated by exercise, suggesting that they may mediate some of the beneficial effects of physical activity on both muscle and neurological function. Targeting myokine signaling pathways represents a theoretical therapeutic approach that may help alleviate muscle wasting and improve overall metabolic and neuromuscular health in patients with PD, though clinical validation is still required.
In PD myokines act as critical mediators in the muscle–brain axis and balancing the “positive” ones (which promote growth and neuroprotection) against the “negative” ones (which drive atrophy and inflammation) is a key therapeutic strategy.
Therapeutic strategies
Exercise is a gold standard for inducing positive myokines like irisin, BDNF, follistatin and suppressing the negative myokines such as myostatin. Other therapeutic approaches include intervention in signaling pathways, administration of pharmaceutical products or even exogenous administration of myokines.
The potential therapeutic targets, signaling mechanisms, and circulating biomarkers related to myokine and neurotrophin signaling are categorized according to the biological and clinical context of the supporting evidence in Table 6.

4.6.1. Myostatin

Myostatin (GDF-8) negatively regulates muscle growth. This myokine belongs to the Activin/Myostatin signaling pathway, a component of the transforming growth factor beta (TGFβ) superfamily that controls muscle development [102]. Activin A also inhibits muscle growth by binding to the same receptor complexes, ActRIIB and ActIIA. Accordingly, administering a soluble activin type IIB receptor (ACVR2B/Fc fusion protein) to mice induced muscle growth by blocking this pathway [103].
While myostatin is linked to muscle atrophy, its role in neurodegeneration-associated cachexia-like syndrome remains understudied. Although physical exercise alters myostatin levels in PD patients, its exact contribution to PD-related muscle atrophy is unclear. An in vivo study showed a significantly higher level of myostatin in sedentary PD mice compared to both healthy controls and exercised PD mice [104]. Additionally, myostatin-induced NF-kB activation in skeletal muscle suggests its involvement in PD muscle atrophy.
Parallel findings in other neurodegenerative disorders support the link with PD. Myostatin was found to be a circulating biomarker for spinal muscular atrophy (SMA). A meta-analysis of datasets from transgenic SMA mice, with gastrocnemian denervation, and muscle samples from patients with type 1 SMA revealed decreased myostatin gene expression across all models [105]. Furthermore, the serum levels were significant lower compared to controls and correlated with disease severity. This suggests that, similar to SMA, the serum myostatin levels could evaluate disease severity and progression in PD.
Therapeutic targets
Research on secondary muscle atrophy in other neurodegenerative diseases offers valuable insights for future PD therapies. For example, inhibiting myostatin/activin A signaling via a soluble ActRIIB receptor completely prevented muscle atrophy and weight loss in a Huntington’s disease mouse model [106].
Other myostatin inhibition strategies include physical exercise, pharmacological follistatin administration, and recombinant adeno-associated virus gene therapy [107].

4.6.2. Follistatin

Follistatin is an endogenous inhibitor of the TGFβ superfamily, including myostatin and activin A, and protects against oxidative stress by reducing ROS [108]. Despite its potential, the direct role of follistatin in PD remains virtually unstudied, leaving a significant gap in current neurodegenerative research. The myostatin/follistatin ratio is a critical marker; it is significantly increased in SMA subjects—inversely correlated with motor severity [105]—and its imbalance drives sarcopenia development [107]. Given that PD also presents severe muscle wasting, a similar biomarker imbalance and pathophysiological mechanism likely apply.
Therapeutic targets
As a therapeutic strategy, follistatin overexpression or administration of a recombinant form induces muscle hypertrophy [109] in rodent models by increasing protein synthesis, muscle mass and force via Akt/mTOR/S6K signaling. However, its therapeutic efficacy may depend heavily on neural integrity [109]. Muscle deprived of functioning motor nerves shows a markedly reduced anabolic response to follistatin. While this denervation model was not directly related to PD, a similar mechanism likely applies. Because the interaction between muscle fibers and motor nerves is compromised in PD, endogenous or exogenous follistatin may lose its expected therapeutic efficacy due to damaged NMJs. Conversely, resistance training remains a viable non-pharmacological strategy in PD, as it effectively increases follistatin levels while simultaneously reducing myostatin [110].

4.6.3. Irisin

Irisin is a soluble peptide which originates from the proteolytic cleavage of a type I transmembrane glycoprotein, fibronectin type III domain-containing protein 5 (FNDC5) [111]. FNDC5 interact with various molecules including BDNF, increasing its expression in the brain [112], and potentially in skeletal muscle. This myokine exerts beneficial effects on both muscle tissue and dopaminergic neurons. In an MPTP mouse model of PD, exogenous irisin treatment rescues motor function and mitigates dopaminergic neurodegeneration by downregulating aberrant brain lactate metabolism via the sirtuin 1 (SIRT1) pathway, thereby suppressing neuroinflammation [113]. Given that muscle tissue under wasting conditions exhibits parallel mitochondrial and inflammatory defects, these central findings offer a strong rationale for peripheral extrapolation.
Physiologically, intramuscular FNDC5 expression and subsequent irisin secretion are driven by physical exercise via the upstream upregulation of the transcriptional coactivatorPGC-1α [114]. Elevated irisin levels successfully counteract muscle atrophy and preserve myofiber mass, with high-intensity resistance training driving more robust circulating expressions than endurance protocols [115].
Beyond structural maintenance, irisin preserve myofiber health by directly modulating mitochondrial quality control [116], and stabilizing metabolic homeostasis. Preclinical models of muscle stress confirm that resistance exercise activates the muscle-autonomous FNDC5-PINK1/Parkin-LC3/P6 mitophagy cascade, scavenging localized ROS pools [117].
Concurrently, human data from non-PD cachectic cohorts indicate that a critical decline in serum irisin correlates tightly with severe muscle mass loss, positioning this peptide as a potential circulating biomarker for muscle atrophy monitoring [118,119].
Therapeutic targets
As an endogenous myokine, irisin represents a target for exploring muscle atrophy mitigation in PD.
This peptide shows experimental capacity in PD models to improve motor function and reduce neuroinflammation by mitigating mitochondrial damage.
Preclinical evidence also suggests that irisin, particularly elevated by resistance training, helps counteract muscle atrophy and supports cellular homeostasis in experimental setups, offering a candidate therapeutic pathway.
Further clinical studies remain essential to evaluate its validity as a biomarker for muscle atrophy.

4.6.4. Brain-Derived Neurotrophic Factor

Brain-derived neurotrophic factor (BDNF), a canonical neurotrophin, operates as an activity-dependent myokine within the muscle–brain axis. During physical contraction, skeletal muscle actively synthesizes and secretes BDNF, which exerts localized anabolic actions, drives myofiber regeneration, and stabilizes the postsynaptic architecture of NMJs [120]. In vivo models confirm that forced treadmill exercise stimulates more robust BDNF transcription across both slow- and fast-twitch muscle fibers compared with voluntary activity [120]. Once secreted, muscle-derived BDNF induces localized lipid oxidation via AMPK activation to sustain energy homeostasis [121]. In geriatric cohorts, circulating BDNF exhibits a powerful protective effect against primary sarcopenia, directly correlating with preserved muscle quality and physical performance [122].
At the synaptic interface, BDNF enhances motor neuron excitability and reinforces synaptic transmission by binding to tyrosine kinase receptor B (TrkB) terminals [123]. In PD patients, altered circulating BDNF levels, together with changes in other NMJ-related biomarkers such as GDNF and CAF22, have been associated with sarcopenia, suggesting their potential value for assessing muscle status [88].
Given that BDNF operates within a complex neurotrophic network, its muscle-autonomous effects are modulated by the pan-neurtrophin receptor p75 (p75NTR)-axis [124]. While p75NTR signaling is traditionally linked to central neuronal apoptosis, emerging evidence indicates that its activation governs peripheral myofiber homeostasis and metabolism [125,126]. Consequently, small-molecule modulators of p75NTR, such as LM11A-31, represent a compelling therapeutic avenue, demonstrating dual efficacy by promoting central neuroprotection while simultaneously stabilizing peripheral muscle homeostasis and metabolic processing [127].
Therapeutic targets
Therapeutic strategies targeting the BDNF network to counteract muscle cachexia-like syndrome can be summarized as follows: TrkB signaling re-activation directly counteracts skeletal muscle wasting by enhancing motor neuron excitability, promoting myofiber regeneration, and stabilizing the degrading NMJ architecture.
Small-molecule p75NTR modulators (e.g., LM11A-31) serve as dual-action therapeutics to rescue muscle wasting by specifically governing peripheral myofiber metabolism, stabilizing glucose uptake, and restoring muscle tissue homeostasis.
Forced exercise protocols act as a non-pharmacological, activity-dependent therapeutic intervention to forcefully drive endogenous BDNF transcription across both slow- and fast-twitch muscle fibers.
Multi-trophic biomarker assessment (BDNF, GDNF, CAF22) may provide complementary information on NMJ-related alterations and sarcopenia in PD; its value for risk stratification or therapeutic monitoring requires further validation.

4.6.5. Decorin

Decorin is a myokine with potential therapeutic value for muscle atrophy in PD because it acts as a direct antagonist to myostatin. While its precise expression profile in PD-associated cachexia-like syndrome remains uninvestigated, its mechanical pathways offer strong therapeutic potential.
In mouse models, overexpression of decorin in skeletal muscle downregulates the core atrophic E3 ubiquitin ligases atrogin-1 and MuRF1, while concurrently upregulating the pro-myogenic factors like Mighty (a downstream target repressed by myostatin), myoblast determination protein 1 (Myod1), and follistatin, helping to protect muscle from atrophic changes [18,128].
Research indicates that physical exercise can raise decorin levels, making it a promising area for further study on mitigating muscle loss in PD [129]. In geriatric cohorts, physiological sarcopenia is characterized by a critical decrease in pro-myogenic factors like decorin, alongside an escalation in catabolic myostatin secretion [130]. Physical exercise can partially reverse this dysregulated axis.
Therapeutic targets
It has been shown that acute resistance exercise increased circulating decorin levels in humans and chronic training increased decorin levels in skeletal muscle in humans and mice. Further research is needed to demonstrate whether decorin may be an important biomarker for muscle atrophy in PD.

4.6.6. Interleukin-6

Interleukin-6 (IL-6) exerts a distinct dual role, operating as a classic pro-inflammatory cytokine during systemic immune responses and as an anti-inflammatory myokine when transiently released by skeletal muscle during physical contraction [131,132]. A clear biological and kinetic distinction must be made between the acute, transient elevation of muscle-derived IL-6 induced by physical exercise and the sustained, chronic elevation of circulating IL-6 driven by systemic inflammation. During physical activity, muscle-derived IL-6 acts as a metabolic and anti-inflammatory myokine; it is released locally in a pulsatile manner without activating upstream pro-inflammatory cascades, working to stimulate muscle glucose uptake via AMPK, enhance fatty acid oxidation, and promote physiological muscle repair.
In PD patients, chronic neuroinflammatory mechanisms drive persistent, low-grade elevations in circulating IL-6, which correlate with cognitive deficits and compromised physical performance [133]. Mechanistically, sustained high levels of pro-inflammatory IL-6—secreted predominantly by immune cells and adypocytes in response to chronic neurodegenerative stress—exert detrimental, catabolic effects. This persistent, pathological exposure impairs basal muscle protein synthesis, disturbs mitochondrial bioenergetics, and drives inflammatory cell infiltration into myofibers via the NF-κB pathway [133]. These effects accelerate muscle cachexia-like syndrome by triggering muscle proteolysis via the ubiquitin–protesome system, impairing insulin sensitivity, and, exacerbating patient fatigue and weakness. Clinically, elevated IL-6 serves as a sensitive marker for increased mortality risk in PD cohorts, tracking advanced neurodegeneration and systemic comorbidities [134].
Therapeutic targets
The therapeutic potential of IL-6 axis requires careful contextualization. While preclinical models show that targeted pharmacological inhibition of pathological IL-6 suppresses atrogene induction and ameliorates disuse-mediated muscle atrophy in vivo, its exercise-induced pulsatile release remains essential for metabolic remodeling [135].
Given its dual role, direct therapeutic targeting of IL-6 in PD requires extensive validation before clinical translation.
Table 6. Myokines as potential therapeutic targets in PD-associated muscle wasting.

5. Current Challenges in the Field and Future Perspectives

While the molecular and cellular pathways reviewed herein highlight promising therapeutic targets, translating these findings from bench to bedside requires overcoming several critical challenges currently present in the global literature.
Foremost among these limitations is the field’s heavy preclinical and translation reliance. A significant proportion of the existing mechanistic data regarding muscle cachexia-like syndrome originates from animal models or non-PD muscle-wasting pathologies. Direct molecular evidence mapping these exact pathways inside human PD skeletal muscle remains scarce. Future research must prioritize clinical biopsies and tissue-specific assays to validate these mechanisms in human cohorts.
Furthermore, clinical translation is severely hindered by widespread methodological and terminological heterogeneity. As established in our conceptual framework, the historical literature frequently uses terms like sarcopenia, muscle wasting, and cachexia interchangeably. This lack of standardization complicates the comparison of cross-sectional studies and clinical trial outcomes, making the adoption of uniform operational definitions an ongoing prerequisite for scientific progression.
This diagnostic ambiguity is further compounded by a critical scarcity of longitudinal data. Current clinical human studies focusing on the brain–muscle axis in PD utilize primarily cross-sectional designs. Consequently, the field lacks robust longitudinal tracking to chart the precise trajectory of muscle degradation from early prodromal stages to advanced motor complications. Longitudinal biobanking and monitoring are essential to establish reliable causal relationships.
Finally, there remains insufficient interventional evidence to guide clinical practice. Although physical exercise and targeted resistance training consistently elevate protective myokines and improve muscle phenotypes, large-scale, randomized controlled trials evaluating specific molecular outcomes remain limited. Future clinical trials must go beyond tracking gross motor scores, incorporating fluid biomarkers and metabolic readouts to firmly establish the efficacy of interventions targeting modifiable muscular pathways. However, even these molecular frameworks undergo translation, implementing physical exercise as a therapeutic protocol in real-world clinical practice introduces profound structural and patient-specific constraints. Patient compliance and long-term adherence are critically hindered by intrinsic non-motor symptoms of PD, most notably central apathy, pain, and severe disease-related fatigue. Furthermore, the physical execution of high-intensity interventions introduces a heightened risk of adverse events, particularly musculoskeletal injuries and falls exacerbated by postural instability, bradykinesia, or sudden freezing of gait (FOG). Clinicians must also navigate significant cardiovascular and autonomic contraindications. Parkinsonian dysautonomia frequently manifests as orthostatic hypotension, a blunted heart rate response to maximal exertion, or supine hypertension, meaning unsupervised or poorly tailored exercises can precipitate severe hemodynamic instability or syncopal episodes. Compounding these clinical hurdles, geographical disparities, structural barriers to specialized neuro-physiotherapy, and the lack of accessible, supervised training environments severely limit the real-world scalability of these interventions, turning a proven physiological therapy into a logistical challenge for advanced PD populations.

6. Conclusions

Muscle cachexia-like syndrome represents a complex, multi-systemic process and an often overlooked component of disease progression in PD, arising from a network connecting neurodegeneration, diminished physical activity, metabolic dysfunction, and systemic inflammation. Increasing evidence suggests that skeletal muscle is not simply a passive target of neurodegenerative processes but an active endocrine and metabolic organ that contributes to whole-body homeostasis. Consequently, evaluating muscle wasting in PD requires a deep understanding of both central and peripheral pathophysiological mechanisms.
Given the current scarcity of clinical data, this condition appears restricted to a distinct subset of PD patients, presenting as muscle weakness and atrophy far more severe than the structural modifications caused by isolated age-related sarcopenia or primary denervation. Because this syndrome is rarely addressed in routine clinical settings, dedicated therapeutic protocols do not yet exist, and current interventions remain largely extrapolated from cachectic states secondary to cancer or sepsis.
Identifying potential therapeutic targets within muscle tissue signaling pathways remains crucial and is a prerequisite for guiding future clinical trials. Rather than viewing individual pathways in isolation, the intersection of proteostatic networks, mitochondrial quality control systems, NMJ stability, and endocrine signaling must be approached as a unified therapeutic lanscape.
To temper translational expectations and realistically guide future drug discovery, these therapeutic targets are explicitly stratified into three tiers based on their supporting human and experimental frameworks (as systematically indexed in the ‘Evidence context’ classifications of Table 2, Table 3, Table 4, Table 5 and Table 6):
•
Targets with human PD evidence (High Potential): This tier represents clinically established or readily scalable interventions supported by extensive human physiological or epidemiological data. Structured physical activity—encompassing targeted aerobic exercise and progressive resistance training—remains the premier non-pharmacological strategy capable of stimulating mitochondrial biogenesis, enhancing respiratory chain efficiency, and restoring physiological autophagic flux. Nevertheless, its clinical implementation in PD is constrained by variable adherence, motor and non-motor symptoms, fall risk, autonomic and cardiovascular dysfunction, and limited access to supervised rehabilitation, requiring individualized exercise prescriptions and appropriate safety assessment. Similarly, modulating the bidirectional crosstalk between systemic insulin resistance and muscle protein homeostasis by repositioning established anti-diabetic drugs represents a highly viable clinical framework due to existing safety profiles in human PD cohorts.
•
Targets with experimental PD evidence (Medium Potential): This tier involves specific molecular axes that show clear, robust efficacy in rodent or in vitro models of muscle degradation but lack extensive clinical validation or face distinct human translation hurdles. This encompasses the use of localized mitochondrial antioxidants (e.g., Mito-TEMPO), upstream muscle kinase stabilizers (SGK1 and Srpk3 signaling), and targeted small-molecule inhibitors aimed at slowing downstream proteolytic systems, such as preventing atrogene activation or achieving synergistic E3 ligase silencing (Fbxl22/MuRF1). Additionally, emerging preclinical data on myokine biology offer promising, though still preclinical, targets in modulating local inflammation and driving myofiber regeneration.
•
Targets which remain hypotheses-generating (Pure Hypothesis/Early-Stage Concepts): This category comprises highly speculative pathways where the underlying pathophysiology is not yet verified in human PD muscle tissue, meaning therapeutic benefits remain entirely theoretical. This includes implementing monoclonal immunotherapies (e.g., prasinezumab) to halt peripheral, cross-tissue aggregate propagation, or utilizing viral-mediated gene therapies (such as AAV-driven Parkin overexpression). Furthermore, exploring the shared upstream epigenetic landscape—including BET proteins, DNA methyltransferases (DNMTs), histone deacetylases (HDACs), and microRNAs (miRNAs)—remains an early-stage future direction that requires direct, tissue-specific evidence in PD-associated cohorts before clinical application can be considered.
Ultimately, transitioning these pharmacological and molecular strategies from strictly experimental configurations to direct clinical applicability remains unproven and requires rigorous, longitudinal human validation.
Merging insights from proteostasis pathways, mitochondrial integrity, NMJ stability, myokine biology, and systemic metabolism will facilitate the formulation of mechanism-based clinical strategies, offering the potential to preserve functional capacity and advance the neuromuscular health of individuals living with PD.

Author Contributions

Conceptualization, E.M. and L.C.C.; investigation, E.M., G.G. and E.M.D.; writing—original draft preparation, E.M., G.G. and E.M.D.; writing—review and editing, E.M., L.C.C. and B.O.P.; supervision, L.C.C. and B.O.P.; project administration, L.C.C. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Romanian Ministry of Research, Innovation and Digitization through the Core Programme, project no. PN 23.16.01.02.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

AbbreviationDefinition
ACVR2B/FcActivin type IIB receptor fusion protein
AktProtein kinase B (also known as PKB)
ALSAmyotrophic lateral sclerosis
AMPKAMP-activated protein kinase
Atrogin-1Muscle atrophy F-box (encoded by the FBXO32 gene)
Bcl-2B-cell lymphoma 2
BDNFBrain-derived neurotrophic factor
BETBromodomain and extraterminal domain
BIABioelectrical Impedance Analysis
BRD4Bromodomain-containing protein 4
BrpBruchpilot presynaptic scaffolding protein
CAF22C-terminal agrin fragment-22
CLEARCoordinated lysosomal expression and regulation network
CRPC-reactive protein
DFODeferoxamine
DMDDuchenne muscular dystrophy
DNMTsDNA methyltransferases
DXADual-energy X-ray absorptiometry
eIF3-FEukaryotic translation initiation factor 3 subunit F
EWGSOP2European Working Group on Sarcopenia in Older People 2 guidelines
Fbxl22F-box and leucine-rich protein 22
FNDC5Fibronectin type III domain-containing protein 5
FoxOForkhead box O
FoxO3Forkhead box O3
GDNFGlial cell line-derived neurotrophic factor
HDACsHistone deacetylases
IBMInclusion body myositis
IL-6Interleukin-6
IRInsulin resistance
IRS-1Insulin receptor substrate 1
JAKJanus kinase
LM11A-31Small-molecule p75NTR modulator laboratory code
LRP4Low-density lipoprotein receptor-related protein 4
MAPKMitogen-activated protein kinase
Mef2Myocyte enhancer factor 2
MightyPro-myogenic factor Mighty (also known as Akirin 1)
miRNAsMicroRNAs
MitoQMitoquinone mesylate
Mito-TEMPOMitochondria-targeted antioxidant
MiT/TFEMicrophthalmia/transcription factor E family
MPTP1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
MuRF1Muscle RING finger 1 (encoded by the TRIM63 gene)
MUSA1Muscle ubiquitin ligase of SCF complex in Atrophy-1
MuSKMuscle-specific kinase
MyoD/Myod1Myoblast determination protein 1
NF-kBNuclear factor kappa-light-chain-enhancer of activated B cells
NMJNeuromuscular junction
Nrf2Nuclear factor erythroid 2-related factor 2
p-AMPKαPhosphorylated 5′ adenosine monophosphate-activated protein kinase α
p62Protein p62 (Sequestosome-1/SQSTM1)
p75NTRp75 neurotrophin receptor
PARISParkin interacting substrate (also known as ZNF746)
PARK2Parkin gene
PDParkinson’s disease
PGC-1αPeroxisome proliferator-activated receptor gamma coactivator 1-alpha
PINK1PTEN-induced putative kinase 1
Rab11Rab11 trafficking protein
ROSReactive oxygen species
S6K1Ribosomal protein S6 kinase beta-1 (also called p70S6K)
SGK1Serum/glucocorticoid-regulated kinase 1
SIRT1Sirtuin 1
SMASpinal muscular atrophy
SMARTSpecific of Muscle Atrophy and Regulated by Transcription
SNCASynuclein Alpha protein-coding gene
SNARESoluble NSF attachment protein receptor
Srpk3Serine/arginine-rich protein-specific kinase 3
TEMPO2,2,6,6-tetramethylpiperidine-1-oxyl chemical group
Tfe3Transcription factor E3
TfebTranscription factor EB
TGFβTransforming growth factor beta
TNF-αTumor necrosis factor alpha
TRAF6TNF receptor-associated factor 6
TrkBTropomyosin receptor kinase B
UPSUbiquitin–proteasome system

References

  1. Magrinelli, F.; Picelli, A.; Tocco, P.; Federico, A.; Roncari, L.; Smania, N.; Zanette, G.; Tamburin, S. Pathophysiology of Motor Dysfunction in Parkinson’s Disease as the Rationale for Drug Treatment and Rehabilitation. Park. Dis. 2016, 2016, 9832839. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  2. Gui, M.; Lv, L.; Hu, S.; Qin, L.; Wang, C. Sarcopenia in Parkinson’s Disease: From Pathogenesis to Interventions. Metabolism 2025, 169, 156272. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  3. Anker, S.D.; Morley, J.E.; Von Haehling, S. Welcome to the ICD-10 Code for Sarcopenia. J. Cachexia Sarcopenia Muscle 2016, 7, 512–514. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  4. Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; et al. Sarcopenia: Revised European Consensus on Definition and Diagnosis. Age Ageing 2019, 48, 16–31. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  5. Hart, A.; Cordova-Rivera, L.; Barker, F.; Sayer, A.A.; Granic, A.; Yarnall, A.J. The Prevalence of Sarcopenia in Parkinson’s Disease and Related Disorders- a Systematic Review. Neurol. Sci. 2023, 44, 4205–4217. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  6. Cai, Y.; Feng, F.; Wei, Q.; Jiang, Z.; Ou, R.; Shang, H. Sarcopenia in Patients With Parkinson’s Disease: A Systematic Review and Meta-Analysis. Front. Neurol. 2021, 12, 598035. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  7. Yong, V.W.; Tan, Y.J.; Ng, Y.-D.; Choo, X.Y.; Sugumaran, K.; Chinna, K.; Md Shah, M.N.; Raja Aman, R.R.A.; Moy, F.M.; Mohd Ramli, N.; et al. Progressive and Accelerated Weight and Body Fat Loss in Parkinson’s Disease: A Three-Year Prospective Longitudinal Study. Park. Relat. Disord. 2020, 77, 28–35. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  8. Morimoto, R.; Kitagawa, K.; Todo, K.; Iijima, M. Clinical Analysis of Sarcopenia Prevalence and Its Influencing Factors in Patients with Parkinson’s Disease. Front. Aging Neurosci. 2025, 17, 1718723. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  9. Murphy, K.T.; Lynch, G.S. Impaired Skeletal Muscle Health in Parkinsonian Syndromes: Clinical Implications, Mechanisms and Potential Treatments. J. Cachexia Sarcopenia Muscle 2023, 14, 1987–2002. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  10. Ali, S.; Garcia, J.M. Sarcopenia, Cachexia and Aging: Diagnosis, Mechanisms and Therapeutic Options—A Mini-Review. Gerontology 2014, 60, 294–305. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  11. Fearon, K.; Strasser, F.; Anker, S.D.; Bosaeus, I.; Bruera, E.; Fainsinger, R.L.; Jatoi, A.; Loprinzi, C.; MacDonald, N.; Mantovani, G.; et al. Definition and Classification of Cancer Cachexia: An International Consensus. Lancet Oncol. 2011, 12, 489–495. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  12. Burtscher, J.; Millet, G.P.; Place, N.; Kayser, B.; Zanou, N. The Muscle-Brain Axis and Neurodegenerative Diseases: The Key Role of Mitochondria in Exercise-Induced Neuroprotection. Int. J. Mol. Sci. 2021, 22, 6479. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  13. Liu, T.; Wu, H.; Wei, J. Beyond the Brain: Exploring the Multi-Organ Axes in Parkinson’s Disease Pathogenesis. J. Adv. Res. 2025, 80, 451–474. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  14. Xu, G.; Ma, C.; Yang, Y. Intervention Strategies for Parkinson’s Disease: The Role of Exercise and Mitochondria. Front. Aging Neurosci. 2025, 17, 1519672. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  15. Lee, B.; Shin, M.; Park, Y.; Won, S.-Y.; Cho, K.S. Physical Exercise-Induced Myokines in Neurodegenerative Diseases. Int. J. Mol. Sci. 2021, 22, 5795. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  16. Mitchell, A.K.; Bliss, R.R.; Church, F.C. Exercise, Neuroprotective Exerkines, and Parkinson’s Disease: A Narrative Review. Biomolecules 2024, 14, 1241. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  17. Magaña, J.C.; Deus, C.M.; Giné-Garriga, M.; Montané, J.; Pereira, S.P. Exercise-Boosted Mitochondrial Remodeling in Parkinson’s Disease. Biomedicines 2022, 10, 3228. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  18. Manole, E.; Ceafalan, L.C.; Popescu, B.O.; Dumitru, C.; Bastian, A.E. Myokines as Possible Therapeutic Targets in Cancer Cachexia. J. Immunol. Res. 2018, 2018, 8260742. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  19. Li, N.; Wang, B.; Wang, Y.; Tian, X.; Lin, J.; Sun, X.; Sun, Y.; Zhang, X.; Xu, H.; Li, M.; et al. Exercise Ameliorates Dysregulated Mitochondrial Fission, Mitochondrial Respiration, and Neuronal Apoptosis in Parkinson’s Disease Mice via the Irisin/AMPK/SIRT1 Pathway. Mol. Neurobiol. 2025, 62, 8843–8856. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  20. Seo, M.H.; Yeo, S. Triadin Decrease Impairs the Expression of E-C Coupling Related Proteins in Muscles of MPTP-Induced Parkinson’s Disease Mice. Front. Neurosci. 2021, 15, 649688. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  21. Sartori, R.; Romanello, V.; Sandri, M. Mechanisms of Muscle Atrophy and Hypertrophy: Implications in Health and Disease. Nat. Commun. 2021, 12, 330. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  22. Taillandier, D.; Polge, C. Skeletal Muscle Atrogenes: From Rodent Models to Human Pathologies. Biochimie 2019, 166, 251–269. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  23. Tan, A.H.; Lim, S.Y.; Lang, A.E. The Microbiome–Gut–Brain Axis in Parkinson Disease—From Basic Research to the Clinic. Nat. Rev. Neurol. 2022, 18, 476–495. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  24. Kiani, L. Parkinson Disease Pathology Can Originate in the Kidney. Nat. Rev. Neurol. 2025, 21, 125. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  25. Askanas, V.; Engel, W.K.; Alvarez, R.B.; McFerrin, J.; Broccolini, A. Novel Immunolocalization of α-Synuclein in Human Muscle of Inclusion-Body Myositis, Regenerating and Necrotic Muscle Fibers, and at Neuromuscular Junctions. J. Neuropathol. Exp. Neurol. 2000, 59, 592–598. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  26. Lautenschläger, J.; Kaminski, C.F.; Kaminski Schierle, G.S. α-Synuclein—Regulator of Exocytosis, Endocytosis, or Both? Trends Cell Biol. 2017, 27, 468–479. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  27. Mu, L.; Sobotka, S.; Chen, J.; Su, H.; Sanders, I.; Adler, C.H.; Shill, H.A.; Caviness, J.N.; Samanta, J.E.; Beach, T.G.; et al. Alpha-Synuclein Pathology and Axonal Degeneration of the Peripheral Motor Nerves Innervating Pharyngeal Muscles in Parkinson Disease. J. Neuropathol. Exp. Neurol. 2013, 72, 119–129. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  28. Yang, Q.; Wang, Y.; Zhao, C.; Pang, S.; Lu, J.; Chan, P. α-Synuclein Aggregation Causes Muscle Atrophy through Neuromuscular Junction Degeneration. J. Cachexia Sarcopenia Muscle 2023, 14, 226–242. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  29. Wijesekara, N.; Ahrens, R.; Wu, L.; Langman, T.; Tandon, A.; Fraser, P.E. α-Synuclein Regulates Peripheral Insulin Secretion and Glucose Transport. Front. Aging Neurosci. 2021, 13, 665348. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  30. Rodriguez-Araujo, G.; Nakagami, H.; Takami, Y.; Katsuya, T.; Akasaka, H.; Saitoh, S.; Shimamoto, K.; Morishita, R.; Rakugi, H.; Kaneda, Y. Low Alpha-Synuclein Levels in the Blood Are Associated with Insulin Resistance. Sci. Rep. 2015, 5, 12081. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  31. Heo, E.-J.; Lee, Y.; Hyung Seo, M.; Yeo, S. Association between SGK1 and α-Synuclein in Skeletal Muscle in an MPTP-Induced Parkinson’s Disease Model. Neurosci. Lett. 2023, 814, 137464. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  32. Seo, M.H.; Yeo, S. Srpk3 Decrease Associated with Alpha-Synuclein Increase in Muscles of MPTP-Induced Parkinson’s Disease Mice. Int. J. Mol. Sci. 2021, 22, 9375. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  33. Sui, Y.-T.; Bullock, K.M.; Erickson, M.A.; Zhang, J.; Banks, W.A. Alpha Synuclein Is Transported into and out of the Brain by the Blood–Brain Barrier. Peptides 2014, 62, 197–202. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  34. Yang, Y.; Nie, X.; Wang, Y.; Sun, J.; Gao, X.; Zhang, J. Evolving Insights into Erythrocytes in Synucleinopathies. Trends Neurosci. 2024, 47, 693–707. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  35. Matsumoto, J.; Stewart, T.; Sheng, L.; Li, N.; Bullock, K.; Song, N.; Shi, M.; Banks, W.A.; Zhang, J. Transmission of α-Synuclein-Containing Erythrocyte-Derived Extracellular Vesicles across the Blood-Brain Barrier via Adsorptive Mediated Transcytosis: Another Mechanism for Initiation and Progression of Parkinson’s Disease? Acta Neuropathol. Commun. 2017, 5, 71. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  36. Gray, M.T.; Woulfe, J.M. Striatal Blood–Brain Barrier Permeability in Parkinson’S Disease. J. Cereb. Blood Flow Metab. 2015, 35, 747–750. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  37. Pienaar, I.S.; Lee, C.H.; Elson, J.L.; McGuinness, L.; Gentleman, S.M.; Kalaria, R.N.; Dexter, D.T. Deep-Brain Stimulation Associates with Improved Microvascular Integrity in the Subthalamic Nucleus in Parkinson’s Disease. Neurobiol. Dis. 2015, 74, 392–405. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  38. Xiao, B.; Tan, E.-K. Prasinezumab Slows Motor Progression in Parkinsons Disease: Beyond the Clinical Data. npj Park. Dis. 2025, 11, 31. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  39. Peker, N.; Donipadi, V.; Sharma, M.; McFarlane, C.; Kambadur, R. Loss of Parkin Impairs Mitochondrial Function and Leads to Muscle Atrophy. Am. J. Physiol.-Cell Physiol. 2018, 315, C164–C185. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  40. Kitada, T.; Asakawa, S.; Hattori, N.; Matsumine, H.; Yamamura, Y.; Minoshima, S.; Yokochi, M.; Mizuno, Y.; Shimizu, N. Mutations in the Parkin Gene Cause Autosomal Recessive Juvenile Parkinsonism. Nature 1998, 392, 605–608. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  41. Reynaud, O.; Ayoub, M.-B.; Leduc-Gaudet, J.-P.; Cefis, M.; Lussier, M.P.; Hussain, S.N.; Gouspillou, G. Parkin Overexpression Attenuates Muscle Atrophy and Improves Mitochondrial Bioenergetics but Fails to Improve Key Histological Features in a Mouse Model of Duchenne Muscular Dystrophy. Sci Rep 2026, 16, 4139. [Google Scholar] [CrossRef] [Scilit]
  42. Sun, T.; Han, Y.; Li, J.-L.; Jiao, X.-Y.; Zuo, L.; Wang, J.; Wang, H.-X.; Yang, J.-L.; Cao, J.-M.; Wang, J.-X. FOXO3a-Dependent PARKIN Negatively Regulates Cardiac Hypertrophy by Restoring Mitophagy. Cell Biosci. 2022, 12, 204. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  43. Gouspillou, G.; Godin, R.; Piquereau, J.; Picard, M.; Mofarrahi, M.; Mathew, J.; Purves-Smith, F.M.; Sgarioto, N.; Hepple, R.T.; Burelle, Y.; et al. Protective Role of Parkin in Skeletal Muscle Contractile and Mitochondrial Function. J. Physiol. 2018, 596, 2565–2579. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  44. Garber, C.E.; Friedman, J.H. Effects of Fatigue on Physical Activity and Function in Patients with Parkinson’s Disease. Neurology 2003, 60, 1119–1124. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  45. Stevens-Lapsley, J.; Kluger, B.M.; Schenkman, M. Quadriceps Muscle Weakness, Activation Deficits, and Fatigue with Parkinson Disease. Neurorehabil. Neural Repair 2012, 26, 533–541. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  46. Esteca, M.V.; Severino, M.B.; Silvestre, J.G.; Palmeira Dos Santos, G.; Tamborlin, L.; Luchessi, A.D.; Moriscot, A.S.; Gustafsson, Å.B.; Baptista, I.L. Loss of Parkin Results in Altered Muscle Stem Cell Differentiation during Regeneration. Int. J. Mol. Sci. 2020, 21, 8007. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  47. Ivankovic, D.; Chau, K.; Schapira, A.H.V.; Gegg, M.E. Mitochondrial and Lysosomal Biogenesis Are Activated Following PINK 1/Parkin-mediated Mitophagy. J. Neurochem. 2016, 136, 388–402. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  48. Shiba-Fukushima, K.; Imai, Y.; Yoshida, S.; Ishihama, Y.; Kanao, T.; Sato, S.; Hattori, N. PINK1-Mediated Phosphorylation of the Parkin Ubiquitin-like Domain Primes Mitochondrial Translocation of Parkin and Regulates Mitophagy. Sci. Rep. 2012, 2, 1002. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  49. Narendra, D.P.; Youle, R.J. The Role of PINK1–Parkin in Mitochondrial Quality Control. Nat. Cell Biol. 2024, 26, 1639–1651. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  50. Geisler, S.; Holmström, K.M.; Treis, A.; Skujat, D.; Weber, S.S.; Fiesel, F.C.; Kahle, P.J.; Springer, W. The PINK1/Parkin-Mediated Mitophagy Is Compromised by PD-Associated Mutations. Autophagy 2010, 6, 871–878. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  51. Shin, J.-H.; Ko, H.S.; Kang, H.; Lee, Y.; Lee, Y.-I.; Pletinkova, O.; Troconso, J.C.; Dawson, V.L.; Dawson, T.M. PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson’s Disease. Cell 2011, 144, 689–702. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  52. Peker, N.; Sharma, M.; Kambadur, R. Parkin Deficiency Exacerbates Fasting-Induced Skeletal Muscle Wasting in Mice. npj Park. Dis. 2022, 8, 159. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  53. Yang, Y.; Gehrke, S.; Imai, Y.; Huang, Z.; Ouyang, Y.; Wang, J.-W.; Yang, L.; Beal, M.F.; Vogel, H.; Lu, B. Mitochondrial Pathology and Muscle and Dopaminergic Neuron Degeneration Caused by Inactivation of Drosophila Pink1 Is Rescued by Parkin. Proc. Natl. Acad. Sci. USA 2006, 103, 10793–10798. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  54. Leduc-Gaudet, J.-P.; Hussain, S.N.A.; Barreiro, E.; Gouspillou, G. Mitochondrial Dynamics and Mitophagy in Skeletal Muscle Health and Aging. Int. J. Mol. Sci. 2021, 22, 8179. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  55. Leduc-Gaudet, J.-P.; Mayaki, D.; Reynaud, O.; Broering, F.E.; Chaffer, T.J.; Hussain, S.N.A.; Gouspillou, G. Parkin Overexpression Attenuates Sepsis-Induced Muscle Wasting. Cells 2020, 9, 1454. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  56. Leduc-Gaudet, J.; Reynaud, O.; Hussain, S.N.; Gouspillou, G. Parkin Overexpression Protects from Ageing-related Loss of Muscle Mass and Strength. J. Physiol. 2019, 597, 1975–1991. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  57. Duranti, E.; Villa, C. From Brain to Muscle: The Role of Muscle Tissue in Neurodegenerative Disorders. Biology 2024, 13, 719. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  58. Marzetti, E.; Calvani, R.; Coelho-Junior, H.J.; Landi, F.; Picca, A. Defective Mitochondrial Quality Control in the Aging of Skeletal Muscle. Mech. Ageing Dev. 2025, 228, 112112. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  59. Kitajima, Y.; Yoshioka, K.; Suzuki, N. The Ubiquitin-Proteasome System in Regulation of the Skeletal Muscle Homeostasis and Atrophy: From Basic Science to Disorders. J. Physiol. Sci. JPS 2020, 70, 40. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  60. Bodine, S.C.; Latres, E.; Baumhueter, S.; Lai, V.K.-M.; Nunez, L.; Clarke, B.A.; Poueymirou, W.T.; Panaro, F.J.; Na, E.; Dharmarajan, K.; et al. Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy. Science 2001, 294, 1704–1708. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  61. Bonaldo, P.; Sandri, M. Cellular and Molecular Mechanisms of Muscle Atrophy. Dis. Model. Mech. 2013, 6, 25–39. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  62. Divino, I.A.; Da Vieira-da-Silva, A.L.; Esteca, M.V.; Tonon, R.P.; Da Cruz, F.O.G.; Braga, R.R.; Ropelle, E.R.; Gandra, P.G.; Baptista, I.L. Absence of Parkin Results in Atrophy of Oxidative Myofibers and Modulation of AKT and MURF1 Signaling in Middle-Aged Male Mice. Acta Physiol. 2025, 241, e70082. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  63. Bowen, T.S.; Adams, V.; Werner, S.; Fischer, T.; Vinke, P.; Brogger, M.N.; Mangner, N.; Linke, A.; Sehr, P.; Lewis, J.; et al. Small-molecule Inhibition of MuRF1 Attenuates Skeletal Muscle Atrophy and Dysfunction in Cardiac Cachexia. J. Cachexia Sarcopenia Muscle 2017, 8, 939–953. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  64. Hughes, D.C.; Baehr, L.M.; Driscoll, J.R.; Lynch, S.A.; Waddell, D.S.; Bodine, S.C. Identification and Characterization of Fbxl22, a Novel Skeletal Muscle Atrophy-Promoting E3 Ubiquitin Ligase. Am. J. Physiol.-Cell Physiol. 2020, 319, C700–C719. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  65. Deval, C.; Mordier, S.; Obled, C.; Bechet, D.; Combaret, L.; Attaix, D.; Ferrara, M. Identification of Cathepsin L as a Differentially Expressed Message Associated with Skeletal Muscle Wasting. Biochem. J. 2001, 360, 143–150. [Google Scholar] [CrossRef]
  66. Hull, A.; Atilano, M.L.; Gergi, L.; Kinghorn, K.J. Lysosomal Storage, Impaired Autophagy and Innate Immunity in Gaucher and Parkinson’s Diseases: Insights for Drug Discovery. Philos. Trans. R. Soc. B Biol. Sci. 2024, 379, 20220381. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  67. Triolo, M.; Hood, D.A. Manifestations of Age on Autophagy, Mitophagy and Lysosomes in Skeletal Muscle. Cells 2021, 10, 1054. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  68. Kim, M.; Semple, I.; Kim, B.; Kiers, A.; Nam, S.; Park, H.-W.; Park, H.; Ro, S.-H.; Kim, J.-S.; Juhász, G.; et al. Drosophila Gyf/GRB10 Interacting GYF Protein Is an Autophagy Regulator That Controls Neuron and Muscle Homeostasis. Autophagy 2015, 11, 1358–1372. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  69. Chen, M.; Dai, Y.; Liu, S.; Fan, Y.; Ding, Z.; Li, D. TFEB Biology and Agonists at a Glance. Cells 2021, 10, 333. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  70. Calissi, G.; Lam, E.W.-F.; Link, W. Therapeutic Strategies Targeting FOXO Transcription Factors. Nat. Rev. Drug Discov. 2021, 20, 21–38. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  71. Ribeiro, D.N.; De Assis, A.P.; Pinto, A.P.; Ropelle, E.R.; Pauli, J.R.; De Freitas, E.C.; Da Silva, A.S.R. Resistance Training as a Modulator of Autophagy in Skeletal Muscle: A Systematic Review of Molecular Mechanisms and Adaptive Responses. Adv. Exerc. Health Sci. 2025, 2, 177–189. [Google Scholar] [CrossRef] [Scilit]
  72. Santilli, V. Clinical Definition of Sarcopenia. Clin. Cases Miner. Bone Metab. 2014, 11, 177–180. [Google Scholar] [CrossRef] [Scilit]
  73. Liu, L.; Li, Y.; Chen, G.; Chen, Q. Crosstalk between Mitochondrial Biogenesis and Mitophagy to Maintain Mitochondrial Homeostasis. J. Biomed. Sci. 2023, 30, 86. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  74. Romanello, V.; Sandri, M. Mitochondrial Quality Control and Muscle Mass Maintenance. Front. Physiol. 2016, 6, 422. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  75. Powers, S.K.; Wiggs, M.P.; Duarte, J.A.; Zergeroglu, A.M.; Demirel, H.A. Mitochondrial Signaling Contributes to Disuse Muscle Atrophy. Am. J. Physiol.-Endocrinol. Metab. 2012, 303, E31–E39. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  76. Julienne, C.M.; Dumas, J.; Goupille, C.; Pinault, M.; Berri, C.; Collin, A.; Tesseraud, S.; Couet, C.; Servais, S. Cancer Cachexia Is Associated with a Decrease in Skeletal Muscle Mitochondrial Oxidative Capacities without Alteration of ATP Production Efficiency. J. Cachexia Sarcopenia Muscle 2012, 3, 265–275. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  77. Cao, Z. Mitochondrial DNA Deletion Mutations Are Concomitant with Ragged Red Regions of Individual, Aged Muscle Fibers: Analysis by Laser-Capture Microdissection. Nucleic Acids Res. 2001, 29, 4502–4508. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  78. Lee, C.M.; Lopez, M.E.; Weindruch, R.; Aiken, J.M. Association of Age-Related Mitochondrial Abnormalities with Skeletal Muscle Fiber Atrophy. Free Radic. Biol. Med. 1998, 25, 964–972. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  79. Yarnall, A.J.; Granic, A.; Waite, S.; Hollingsworth, K.G.; Warren, C.; Vincent, A.E.; Turnbull, D.M.; Taylor, R.W.; Dodds, R.M.; Sayer, A.A. The Feasibility of Muscle Mitochondrial Respiratory Chain Phenotyping across the Cognitive Spectrum in Parkinson’s Disease. Exp. Gerontol. 2020, 138, 110997. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  80. Kverneng, S.U.; Stige, K.E.; Berven, H.; Mostafavi, S.; Lundervold, K.; Brischigliaro, M.; Brakedal, B.; Skeie, G.O.; Flønes, I.H.; Toker, L.; et al. Mitochondrial Complex I Deficiency Occurs in Skeletal Muscle of a Subgroup of Individuals with Parkinson’s Disease. Commun. Med. 2025, 5, 141. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  81. Mendes, D.; Peixoto, F.; Oliveira, M.M.; Andrade, P.B.; Videira, R.A. Mitochondrial Dysfunction in Skeletal Muscle of Rotenone-Induced Rat Model of Parkinson’s Disease: SC-Nanophytosomes as Therapeutic Approach. Int. J. Mol. Sci. 2023, 24, 16787. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  82. Romanello, V.; Guadagnin, E.; Gomes, L.; Roder, I.; Sandri, C.; Petersen, Y.; Milan, G.; Masiero, E.; Del Piccolo, P.; Foretz, M.; et al. Mitochondrial Fission and Remodelling Contributes to Muscle Atrophy. EMBO J. 2010, 29, 1774–1785. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  83. Guardia-Laguarta, C.; Area-Gomez, E.; Rüb, C.; Liu, Y.; Magrané, J.; Becker, D.; Voos, W.; Schon, E.A.; Przedborski, S. α-Synuclein Is Localized to Mitochondria-Associated ER Membranes. J. Neurosci. 2014, 34, 249–259. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  84. Luth, E.S.; Stavrovskaya, I.G.; Bartels, T.; Kristal, B.S.; Selkoe, D.J. Soluble, Prefibrillar α-Synuclein Oligomers Promote Complex I-Dependent, Ca2+-Induced Mitochondrial Dysfunction. J. Biol. Chem. 2014, 289, 21490–21507. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  85. Wang, Q.; Sun, Y.; Li, T.Y.; Auwerx, J. Mitophagy in the Pathogenesis and Management of Disease. Cell Res. 2026, 36, 11–37. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  86. Kelly, N.A.; Hammond, K.G.; Bickel, C.S.; Windham, S.T.; Tuggle, S.C.; Bamman, M.M. Effects of Aging and Parkinson’s Disease on Motor Unit Remodeling: Influence of Resistance Exercise Training. J. Appl. Physiol. 2018, 124, 888–898. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  87. Caviness, J.N.; Smith, B.E.; Stevens, J.C.; Adler, C.H.; Caselli, R.J.; Reiners, C.A.; Hentz, J.G.; Muenter, M.D. Motor Unit Changes in Sporadic Idiopathic Parkinson’s Disease. Mov. Disord. 2000, 15, 238–243. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  88. Karim, A.; Iqbal, M.S.; Muhammad, T.; Qaisar, R. Evaluation of Sarcopenia Using Biomarkers of the Neuromuscular Junction in Parkinson’s Disease. J. Mol. Neurosci. 2022, 72, 820–829. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  89. Rai, P.; Ratnaparkhi, A.; Kumar Roy, J. Rab11 Rescues Muscle Degeneration and Synaptic Morphology in the Park/+ Parkinson Model of Drosophila Melanogaster. Brain Res. 2023, 1816, 148442. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  90. Fujitani, M.; Tarif, A.M.M.; Otani, Y. Regeneration Mechanisms and Therapeutic Strategies for Neuromuscular Junctions in Aging and Diseases. Neural Regen. Res. 2025, 20, 193–194. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  91. Mitchell, C.L.; Kurouski, D. Novel Strategies in Parkinson’s Disease Treatment: A Review. Front. Mol. Neurosci. 2024, 17, 1431079. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  92. Qaisar, R. Targeting Neuromuscular Junction to Treat Neuromuscular Disorders. Life Sci. 2023, 333, 122186. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  93. Segatto, M.; Fittipaldi, R.; Pin, F.; Sartori, R.; Dae Ko, K.; Zare, H.; Fenizia, C.; Zanchettin, G.; Pierobon, E.S.; Hatakeyama, S.; et al. Epigenetic Targeting of Bromodomain Protein BRD4 Counteracts Cancer Cachexia and Prolongs Survival. Nat. Commun. 2017, 8, 1707. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  94. Winkler-Stuck, K.; Kirches, E.; Mawrin, C.; Dietzmann, K.; Lins, H.; Wallesch, C.-W.; Kunz, W.S.; Wiedemann, F.R. Re-Evaluation of the Dysfunction of Mitochondrial Respiratory Chain in Skeletal Muscle of Patients with Parkinson’s Disease. J. Neural Transm. 2005, 112, 499–518. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  95. Xu, H.; Ranjit, R.; Richardson, A.; Van Remmen, H. Muscle Mitochondrial Catalase Expression Prevents Neuromuscular Junction Disruption, Atrophy, and Weakness in a Mouse Model of Accelerated Sarcopenia. J. Cachexia Sarcopenia Muscle 2021, 12, 1582–1596. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  96. Zhang, L.; Reyes, A.; Wang, X. The Role of Mitochondria-Targeted Antioxidant MitoQ in Neurodegenerative Disease. Mol. Cell. Ther. 2018, 6, 1. [Google Scholar] [CrossRef] [Scilit]
  97. Mayer, C.; Riera-Ponsati, L.; Kauppinen, S.; Klitgaard, H.; Erler, J.T.; Hansen, S.N. Targeting the NRF2 Pathway for Disease Modification in Neurodegenerative Diseases: Mechanisms and Therapeutic Implications. Front. Pharmacol. 2024, 15, 1437939. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  98. Lei, L.; Yuan, J.; Dai, Z.; Xiang, S.; Tu, Q.; Cui, X.; Zhai, S.; Chen, X.; He, Z.; Fang, B.; et al. Targeting the Labile Iron Pool with Engineered DFO Nanosheets to Inhibit Ferroptosis for Parkinson’s Disease Therapy. Adv. Mater. 2024, 36, 2409329. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  99. Li, Y.; Xia, Y.; Yin, S.; Wan, F.; Hu, J.; Kou, L.; Sun, Y.; Wu, J.; Zhou, Q.; Huang, J.; et al. Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson’s Disease. Front. Immunol. 2021, 12, 719807. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  100. Martella, N.; Pensabene, D.; Colardo, M.; Muzzi, M.; Bisesto, E.; Varone, M.; Caretti, G.; Di Porzio, A.; Barrella, V.; Mazzoli, A.; et al. Modulation of Bromo- and Extra-Terminal Domain (BET) Proteins Exerts Neuroprotective Effects in Cell Culture Models of Parkinson’s Disease. Biomedicines 2026, 14, 244. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  101. Trezzi, I.; Rizzo, G.; Giampieri, F.; Battino, M.; Baroni, L. Exploring the Role of Food and Food-Related Compounds in Parkinson’s Disease. Foods 2026, 15, 514. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  102. Lee, S.-J.; Lehar, A.; Meir, J.U.; Koch, C.; Morgan, A.; Warren, L.E.; Rydzik, R.; Youngstrom, D.W.; Chandok, H.; George, J.; et al. Targeting Myostatin/Activin A Protects against Skeletal Muscle and Bone Loss during Spaceflight. Proc. Natl. Acad. Sci. USA 2020, 117, 23942–23951. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  103. Lee, S.-J.; Reed, L.A.; Davies, M.V.; Girgenrath, S.; Goad, M.E.P.; Tomkinson, K.N.; Wright, J.F.; Barker, C.; Ehrmantraut, G.; Holmstrom, J.; et al. Regulation of Muscle Growth by Multiple Ligands Signaling through Activin Type II Receptors. Proc. Natl. Acad. Sci. USA 2005, 102, 18117–18122. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  104. Erekat, N.S.; Al-Jarrah, M.D. Endurance Exercise Training Suppresses Myostatin Upregulation and Nuclear Factor-Kappa B Activation in a Mouse Model of Parkinson’s Disease. Vet. World 2022, 15, 383–389. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  105. De Albuquerque, A.L.A.; Chadanowicz, J.K.; Giudicelli, G.C.; Staub, A.L.P.; Weber, A.C.; Silva, J.M.D.S.; Becker, M.M.; Kowalski, T.W.; Siebert, M.; Saute, J.A.M. Serum Myostatin as a Candidate Disease Severity and Progression Biomarker of Spinal Muscular Atrophy. Brain Commun. 2024, 6, fcae062. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  106. Bondulich, M.K.; Jolinon, N.; Osborne, G.F.; Smith, E.J.; Rattray, I.; Neueder, A.; Sathasivam, K.; Ahmed, M.; Ali, N.; Benjamin, A.C.; et al. Myostatin Inhibition Prevents Skeletal Muscle Pathophysiology in Huntington’s Disease Mice. Sci. Rep. 2017, 7, 14275. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  107. Skrzypczak, D.; Skrzypczak-Zielińska, M.; Ratajczak, A.E.; Szymczak-Tomczak, A.; Eder, P.; Słomski, R.; Dobrowolska, A.; Krela-Kaźmierczak, I. Myostatin and Follistatin—New Kids on the Block in the Diagnosis of Sarcopenia in IBD and Possible Therapeutic Implications. Biomedicines 2021, 9, 1301. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  108. López-Otín, C.; Blasco, M.A.; Partridge, L.; Serrano, M.; Kroemer, G. The Hallmarks of Aging. Cell 2013, 153, 1194–1217. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  109. Sepulveda, P.V.; Lamon, S.; Hagg, A.; Thomson, R.E.; Winbanks, C.E.; Qian, H.; Bruce, C.R.; Russell, A.P.; Gregorevic, P. Evaluation of Follistatin as a Therapeutic in Models of Skeletal Muscle Atrophy Associated with Denervation and Tenotomy. Sci. Rep. 2015, 5, 17535. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  110. Khalafi, M.; Aria, B.; Symonds, M.E.; Rosenkranz, S.K. The Effects of Resistance Training on Myostatin and Follistatin in Adults: A Systematic Review and Meta-Analysis. Physiol. Behav. 2023, 269, 114272. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  111. Osuch, B.; Młotkowska, P.; Marciniak, E.; Misztal, T. Irisin as a Regulator of Brain Energy Homeostasis: Implications for Age-Related Neurodegenerative Diseases. Cells 2026, 15, 603. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  112. Lee, J.M.; Sim, T.H.; Kim, S.H.; Choi, Y.J.; Lee, J.H.; Yeo, S.G.; Kim, Y.-J. Exercise-Induced FNDC5/Irisin Ameliorates Cognitive Impairment in Aged Mice, Associated with Antioxidant and Neurotrophic Responses. Antioxidants 2025, 14, 1239. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  113. Cai, L.; Liu, Y.; Tang, S.; Deng, S.; Zhang, L.; Liao, X.; Zhang, B.; Han, B.; Xie, R. Irisin Inhibits Dopaminergic Neuron Lactate Metabolism and Repairs Mitochondrial Function to Alleviate Parkinson’s Disease by Activating SIRT1 Signaling Pathway. Commun. Biol. 2025, 8, 1516. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  114. Boström, P.; Wu, J.; Jedrychowski, M.P.; Korde, A.; Ye, L.; Lo, J.C.; Rasbach, K.A.; Boström, E.A.; Choi, J.H.; Long, J.Z.; et al. A PGC1-α-Dependent Myokine That Drives Brown-Fat-like Development of White Fat and Thermogenesis. Nature 2012, 481, 463–468. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  115. Li, W.-Q.; Yang, J.-H.; Liu, L.-L.; Ding, S.-T.; Yu, B.; Jiang, L.; Yan, N.; Liu, H.-D. Exercise as a Multitarget Therapy: Modulating Myokines, Neurotrophins, and Inflammation in Parkinson’s Disease. Front. Aging Neurosci. 2025, 17, 1580029. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  116. Zhao, C.; Wu, Y.; Zhu, S.; Liu, H.; Xu, S. Irisin Protects Musculoskeletal Homeostasis via a Mitochondrial Quality Control Mechanism. Int. J. Mol. Sci. 2024, 25, 10116. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  117. Li, H.; Qin, S.; Liang, Q.; Xi, Y.; Bo, W.; Cai, M.; Tian, Z. Exercise Training Enhances Myocardial Mitophagy and Improves Cardiac Function via Irisin/FNDC5-PINK1/Parkin Pathway in MI Mice. Biomedicines 2021, 9, 701. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  118. Oflazoglu, U.; Caglar, S.; Yılmaz, H.E.; Önal, H.T.; Varol, U.; Salman, T.; Yildiz, Y.; Unal, S.; Guc, Z.G.; Kucukzeybek, Y.; et al. The Relationship between Sarcopenia Detected in Newly Diagnosed Colorectal Cancer Patients and FGF21, Irisin and CRP Levels. Eur. Geriatr. Med. 2022, 13, 795–803. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  119. Park, H.-S.; Kim, H.C.; Zhang, D.; Yeom, H.; Lim, S.-K. The Novel Myokine Irisin: Clinical Implications and Potential Role as a Biomarker for Sarcopenia in Postmenopausal Women. Endocrine 2019, 64, 341–348. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  120. Rentería, I.; García-Suárez, P.C.; Fry, A.C.; Moncada-Jiménez, J.; Machado-Parra, J.P.; Antunes, B.M.; Jiménez-Maldonado, A. The Molecular Effects of BDNF Synthesis on Skeletal Muscle: A Mini-Review. Front. Physiol. 2022, 13, 934714. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  121. Matthews, V.B.; Åström, M.-B.; Chan, M.H.S.; Bruce, C.R.; Krabbe, K.S.; Prelovsek, O.; Åkerström, T.; Yfanti, C.; Broholm, C.; Mortensen, O.H.; et al. Brain-Derived Neurotrophic Factor Is Produced by Skeletal Muscle Cells in Response to Contraction and Enhances Fat Oxidation via Activation of AMP-Activated Protein Kinase. Diabetologia 2009, 52, 1409–1418. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  122. Wojszel, A.; Śliwowski, J.; Rentflejsz, J.; Rogalska, J.; Brzóska, M.M.; Wojszel, Z.B. Irisin, Brain-Derived Neurotrophic Factor (BDNF), and Redox Balance in Geriatric Dynapenia. Antioxidants 2025, 14, 1268. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  123. Hurtado, E.; Cilleros, V.; Nadal, L.; Simó, A.; Obis, T.; Garcia, N.; Santafé, M.M.; Tomàs, M.; Halievski, K.; Jordan, C.L.; et al. Muscle Contraction Regulates BDNF/TrkB Signaling to Modulate Synaptic Function through Presynaptic cPKCα and cPKCβI. Front. Mol. Neurosci. 2017, 10, 147. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  124. Ali, N.H.; Al-kuraishy, H.M.; Al-Gareeb, A.I.; Alnaaim, S.A.; Saad, H.M.; Batiha, G.E.-S. The Molecular Pathway of P75 Neurotrophin Receptor (p75NTR) in Parkinson’s Disease: The Way of New Inroads. Mol. Neurobiol. 2024, 61, 2469–2480. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  125. Pérez, V.; Aedo-Cares, S.; Bermedo-García, F.; Mella, J.; Uribe-Martínez, C.; Bronfman, F.C.; Henríquez, J.P. P75 Neurotrophin Receptor Preserves Neuromuscular Synapse Stability and Muscle Strength during Aging. npj Aging 2026, 12, 105. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  126. Pérez, V.; Bermedo-Garcia, F.; Zelada, D.; Court, F.A.; Pérez, M.Á.; Fuenzalida, M.; Ábrigo, J.; Cabello-Verrugio, C.; Moya-Alvarado, G.; Tapia, J.C.; et al. The p75NTR Neurotrophin Receptor Is Required to Organize the Mature Neuromuscular Synapse by Regulating Synaptic Vesicle Availability. Acta Neuropathol. Commun. 2019, 7, 147. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  127. Pallottini, V.; Colardo, M.; Tonini, C.; Martella, N.; Strimpakos, G.; Colella, B.; Tirassa, P.; Bartolomeo, S.D.; Segatto, M. ProNGF/p75NTR Axis Drives Fiber Type Specification by Inducing the Fast-Glycolytic Phenotype in Mouse Skeletal Muscle Cells. Cells 2020, 9, 2232. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  128. Tabone, M. Muscle Mechanics in Metabolic Health and Longevity: The Biochemistry of Training Adaptations. BioChem 2025, 5, 37. [Google Scholar] [CrossRef] [Scilit]
  129. Kanzleiter, T.; Rath, M.; Görgens, S.W.; Jensen, J.; Tangen, D.S.; Kolnes, A.J.; Kolnes, K.J.; Lee, S.; Eckel, J.; Schürmann, A.; et al. The Myokine Decorin Is Regulated by Contraction and Involved in Muscle Hypertrophy. Biochem. Biophys. Res. Commun. 2014, 450, 1089–1094. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  130. Marmondi, F.; Ferrando, V.; Filipas, L.; Codella, R.; Ruggeri, P.; La Torre, A.; Faelli, E.L.; Bonato, M. Exercise-Induced Biomarker Modulation in Sarcopenia: From Inflamm-Aging to Muscle Regeneration. Sports 2025, 13, 444. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  131. Muñoz-Cánoves, P.; Scheele, C.; Pedersen, B.K.; Serrano, A.L. Interleukin-6 Myokine Signaling in Skeletal Muscle: A Double-edged Sword? FEBS J. 2013, 280, 4131–4148. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  132. Nara, H.; Watanabe, R. Anti-Inflammatory Effect of Muscle-Derived Interleukin-6 and Its Involvement in Lipid Metabolism. Int. J. Mol. Sci. 2021, 22, 9889. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  133. Scalzo, P.; Kümmer, A.; Cardoso, F.; Teixeira, A.L. Serum Levels of Interleukin-6 Are Elevated in Patients with Parkinson’s Disease and Correlate with Physical Performance. Neurosci. Lett. 2010, 468, 56–58. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  134. Dufek, M.; Rektorova, I.; Thon, V.; Lokaj, J.; Rektor, I. Interleukin-6 May Contribute to Mortality in Parkinson’s Disease Patients: A 4-Year Prospective Study. Park. Dis. 2015, 2015, 898192. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  135. Yakabe, M.; Ogawa, S.; Ota, H.; Iijima, K.; Eto, M.; Ouchi, Y.; Akishita, M. Inhibition of Interleukin-6 Decreases Atrogene Expression and Ameliorates Tail Suspension-Induced Skeletal Muscle Atrophy. PLoS ONE 2018, 13, e0191318. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Article metric data becomes available approximately 24 hours after publication online.